<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for trachoma - Evans, JR - 2019 | Cochrane Library</title> <meta content="Antibiotics for trachoma - Evans, JR - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for trachoma - Evans, JR - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001860.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for trachoma" name="citation_title"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="jennifer.evans@lshtm.ac.uk" name="citation_author_email"/> <meta content="Anthony W Solomon" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Rahul Kumar" name="citation_author"/> <meta content="King George's Medical University" name="citation_author_institution"/> <meta content="Ángela Perez" name="citation_author"/> <meta content="Health Technology Assessment Institute" name="citation_author_institution"/> <meta content="Balendra P Singh" name="citation_author"/> <meta content="King George's Medical University" name="citation_author_institution"/> <meta content="Rajat Mohan Srivastava" name="citation_author"/> <meta content="King George's Medical University" name="citation_author_institution"/> <meta content="Emma Harding‐Esch" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001860.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Drug Resistance, Bacterial; Administration, Oral; Administration, Topical; Anti‐Bacterial Agents [*administration &amp; dosage, *therapeutic use]; Chlamydia trachomatis [drug effects]; Randomized Controlled Trials as Topic; Trachoma [*drug therapy]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001860.pub4&amp;doi=10.1002/14651858.CD001860.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001860\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001860\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fr","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001860.pub4",title:"Antibiotics for trachoma",firstPublishedDate:"Sep 25, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001860.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001860.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001860.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001860.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001860.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001860.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001860.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001860.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001860.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001860.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4074 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001860.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0139"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-sec-0133"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/appendices#CD001860-sec-0144"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/table_n/CD001860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/table_n/CD001860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for trachoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jennifer R Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0003">Anthony W Solomon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0004">Rahul Kumar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0005">Ángela Perez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0006">Balendra P Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0007">Rajat Mohan Srivastava</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information#CD001860-cr-0008">Emma Harding‐Esch</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information/en#CD001860-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001860.pub4">https://doi.org/10.1002/14651858.CD001860.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001860-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001860-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001860-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001860-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001860-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001860-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001860-abs-0001" lang="en"> <section id="CD001860-sec-0001"> <h3 class="title" id="CD001860-sec-0001">Background</h3> <p>Trachoma is the world's leading infectious cause of blindness. In 1996, WHO launched the Alliance for the Global Elimination of Trachoma by the year 2020, based on the 'SAFE' strategy (surgery, antibiotics, facial cleanliness, and environmental improvement). </p> </section> <section id="CD001860-sec-0002"> <h3 class="title" id="CD001860-sec-0002">Objectives</h3> <p>To assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma (primary objective), <i>Chlamydia trachomatis</i> infection of the conjunctiva, antibiotic resistance, and adverse effects (secondary objectives). </p> </section> <section id="CD001860-sec-0003"> <h3 class="title" id="CD001860-sec-0003">Search methods</h3> <p>We searched relevant electronic databases and trials registers. The date of the last search was 4 January 2019. </p> </section> <section id="CD001860-sec-0004"> <h3 class="title" id="CD001860-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that satisfied either of two criteria: (a) trials in which topical or oral administration of an antibiotic was compared to placebo or no treatment in people or communities with trachoma, (b) trials in which a topical antibiotic was compared with an oral antibiotic in people or communities with trachoma. We also included studies addressing different dosing strategies in the population.  </p> </section> <section id="CD001860-sec-0005"> <h3 class="title" id="CD001860-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD001860-sec-0006"> <h3 class="title" id="CD001860-sec-0006">Main results</h3> <p>We identified 14 studies where individuals with trachoma were randomised and 12 cluster‐randomised studies.  </p> <p><i>Any antibiotic versus control (individuals)</i> </p> <p>Nine studies (1961 participants) randomised individuals with trachoma to antibiotic or control (no treatment or placebo). All of these studies enrolled children and young people with active trachoma. The antibiotics used in these studies included topical (oxy)tetracycline (5 studies), doxycycline (2 studies), and sulfonamides (4 studies). Four studies had more than two study arms. In general these studies were poorly reported, and it was difficult to judge risk of bias. </p> <p>These studies provided low‐certainty evidence that people with active trachoma treated with antibiotics experienced a reduction in active trachoma at three months (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.69 to 0.89; 1961 people; 9 RCTs; I<sup>2</sup> = 73%) and 12 months (RR 0.74, 95% CI 0.55 to 1.00; 1035 people; 4 RCTs; I<sup>2</sup> = 90%). Low‐certainty evidence was available for ocular infection at three months (RR 0.81, 95% CI 0.63 to 1.04; 297 people; 4 RCTs; I<sup>2</sup> = 0%) and 12 months (RR 0.25, 95% CI 0.08 to 0.78; 129 people; 1 RCT). None of these studies assessed antimicrobial resistance. In those studies that reported harms, no serious adverse effects were reported (low‐certainty evidence). </p> <p><i>Oral versus topical antibiotics (individuals)</i> </p> <p>Eight studies (1583 participants) compared oral and topical antibiotics. Only one study included people older than 21 years of age. Oral antibiotics included azithromycin (5 studies), sulfonamides (2 studies), and doxycycline (1 study). Topical antibiotics included (oxy)tetracycline (6 studies), azithromycin (1 study), and sulfonamide (1 study). These studies were poorly reported, and it was difficult to judge risk of bias. </p> <p>There was low‐certainty evidence of little or no difference in effect between oral and topical antibiotics on active trachoma at three months (RR 0.97, 95% CI 0.81 to 1.16; 953 people; 6 RCTs; I<sup>2</sup> = 63%) and 12 months (RR 0.93, 95% CI 0.75 to 1.15; 886 people; 5 RCTs; I<sup>2</sup> = 56%). There was very low‐certainty evidence for ocular infection at three or 12 months. Antimicrobial resistance was not assessed. In those studies that reported adverse effects, no serious adverse effects were reported; one study reported abdominal pain with azithromycin; one study reported a couple of cases of nausea with azithromycin; and one study reported three cases of reaction to sulfonamides (low‐certainty evidence). </p> <p><i>Oral azithromycin versus control (communities)</i> </p> <p>Four cluster‐randomised studies compared antibiotic with no or delayed treatment. Data were available on active trachoma at 12 months from two studies but could not be pooled because of reporting differences. One study at low risk of bias found a reduced prevalence of active trachoma 12 months after a single dose of azithromycin in communities with a high prevalence of infection (RR 0.58, 95% CI 0.52 to 0.65; 1247 people). The other, lower quality, study in low‐prevalence communities reported similar median prevalences of infection at 12 months: 9.3% in communities treated with azithromycin and 8.2% in untreated communities. We judged this moderate‐certainty evidence for a reduction in active trachoma with treatment, downgrading one level for inconsistency between the two studies. Two studies reported ocular infection at 12 months and data could be pooled. There was a reduction in ocular infection (RR 0.36, 0.31 to 0.43; 2139 people) 12 months after mass treatment with a single dose compared with no treatment (moderate‐certainty evidence). There was high‐certainty evidence of an increased risk of resistance of <i>Streptococcus pneumoniae</i> , <i>Staphylococcus aureus</i> , and <i>Escherichia coli</i> to azithromycin, tetracycline, and clindamycin in communities treated with azithromycin, with approximately 5‐fold risk ratios at 12 months. The evidence did not support increased resistance to penicillin or trimethoprim‐sulfamethoxazole. None of the studies measured resistance to <i>C trachomatis</i>. No serious adverse events were reported. The main adverse effect noted for azithromycin (˜10%) was abdominal pain, vomiting, and nausea. </p> <p><i>Oral azithromycin versus topical tetracycline (communities)</i> </p> <p>Three cluster‐randomised studies compared oral azithromycin with topical tetracycline. The evidence was inconsistent for active trachoma and ocular infection at three and 12 months (low‐certainty evidence) and was not pooled due to considerable heterogeneity. Antimicrobial resistance and adverse effects were not reported. </p> <p><i>Different dosing strategies</i> </p> <p>Six studies compared different strategies for dosing. There were: mass treatment at different dosing intervals; applying cessation or stopping rules to mass treatment; strategies to increase mass treatment coverage. There was no strong evidence to support any variation in the recommended annual mass treatment. </p> </section> <section id="CD001860-sec-0007"> <h3 class="title" id="CD001860-sec-0007">Authors' conclusions</h3> <p>Antibiotic treatment may reduce the risk of active trachoma and ocular infection in people infected with <i>C trachomatis</i>, compared to no treatment/placebo, but the size of the treatment effect in individuals is uncertain. Mass antibiotic treatment with single dose oral azithromycin reduces the prevalence of active trachoma and ocular infection in communities. There is no strong evidence to support any variation in the recommended periodicity of annual mass treatment. There is evidence of an increased risk of antibiotic resistance at 12 months in communities treated with antibiotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001860-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001860-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001860-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001860-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001860-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001860-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001860-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001860-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001860-abs-0005" lang="en"> <h3>Antibiotics for trachoma</h3> <p><b>What is the aim of this review?</b><br/> The aim of this Cochrane Review was to find out if antibiotics work for treating trachoma, either in individuals or communities. Cochrane researchers collected and analysed all relevant studies to answer this question and found 26 studies. </p> <p><b>Key messages</b><br/> The review shows that antibiotic treatment of people and communities with trachoma leads to less eye infection due to trachoma and less eye disease. Mass treatment of communities with antibiotics is associated with increased antimicrobial resistance. </p> <p><b>What was studied in the review?</b><br/> Trachoma is caused by a kind of bacterial infection of the outer eye which, if not treated, can lead to blindness. This germ is known as <i>Chlamydia trachomatis</i>, which thrives where water is scarce and hygiene is poor. Trachoma is the most common infectious cause of vision loss and usually affects people living in poor communities. Repeated bouts of conjunctivitis (inflammation of the membrane that covers the surface of the eyeball and inside of the eyelids) known as 'active trachoma' caused by this eye infection can lead to inward turning of the upper eyelid. The eyelashes rub the clear front part of the eye (cornea) leading to pain, scarring, and blindness. </p> <p>The World Health Organization (WHO) has developed the SAFE strategy to eliminate trachoma.</p> <p>• <b>S</b> urgery for inward‐turning eyelids<br/> • <b>A</b> ntibiotics to clear the eye infection<br/> • <b>F</b> acial cleanliness to stop the eye infection being passed on<br/> • <b>E</b>nvironmental improvement, in particular clean water and sanitation </p> <p>This review considers the <b>A</b> part of the SAFE strategy<b>.</b> Antibiotics can be used to treat the eye infection and may be given as an ointment or by mouth. The two antibiotics commonly used for the treatment of trachoma are azithromycin (single dose by mouth) and tetracycline (ointment applied to the eye over several weeks). </p> <p><b>What are the main results of the review?</b><br/> Cochrane researchers found 26 relevant studies. </p> <p>Fourteen studies enrolled people with trachoma. These studies took place in the following WHO regions (one study took place in two regions): African Region (three studies), Eastern Mediterranean Region (five studies), Region of the Americas (four studies), South‐East Asian Region (one study), and Western Pacific Region (two studies). Most of the studies enrolled children and young people with active trachoma. </p> <p>These studies showed that: </p> <p>⇒  people with trachoma treated with antibiotics may have less active trachoma and eye infection at three and 12 months after treatment (low‐certainty evidence); </p> <p>⇒  there may be little or no difference in active trachoma between oral and topical antibiotics at three months and 12 months (low‐certainty evidence) but there was only very low‐certainty evidence on eye infection at three and 12 months; </p> <p>⇒  there were no reports of serious adverse effects. The most common adverse effect reported was nausea with azithromycin.  </p> <p>Twelve studies enrolled communities in areas where trachoma is common and treated the whole community ('mass treatment'). These studies took place mainly in the African Region (10 studies), with one study in the Eastern Mediterranean Region (Egypt) and one study in the Western Pacific Region (Vietnam). </p> <p>These studies showed that: </p> <p>⇒  communities treated with azithromycin had less trachoma (active trachoma and eye infection) 12 months after a single dose treatment (moderate‐certainty evidence); </p> <p>⇒  there was no strong evidence to support changing from the currently recommended strategy of mass treatment of affected communities every year; </p> <p>⇒  there was an increased risk of antimicrobial resistance in treated communities (high‐certainty evidence).  </p> <p><b>How up‐to‐date is this review?</b><br/> Cochrane researchers searched for studies that had been published up to 4 January 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001860-sec-0139" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001860-sec-0139"></div> <h3 class="title" id="CD001860-sec-0140">Implications for practice</h3> <section id="CD001860-sec-0140"> <p>Oral or topical antibiotic treatment reduces the risk of active trachoma and ocular chlamydial infection in people who have active trachoma, but the size of the treatment effect in individuals is uncertain. It is likely that oral azithromycin and topical tetracycline have similar effects if used as prescribed. Mass antibiotic treatment with single dose oral azithromycin reduces the prevalence of active trachoma and ocular infection in communities. There is evidence of an increased risk of antibiotic resistance in communities treated with antibiotics. </p> <p>The evidence provided in this review supports the current "A" strategy as set out by the World Health Organization (WHO) (<a href="./references#CD001860-bbs2-0125" title="SolomonAW , ZondervanM , KuperH , BuchanJC , MabeyDC , FosterA . Trachoma Control: a Guide for Programme Managers. Geneva: World Health Organization, 2006. ">Solomon 2006</a>; <a href="./references#CD001860-bbs2-0135" title="World Health Organization. World Health Organization Strategic and Technical Advisory Group on Neglected Tropical Diseases. Monitoring and Evaluation Working Group Sub‐Group 2. Technical Consultation on Trachoma Surveillance; 2014 September 11−12, 2014 Task Force for Global Health; Decatur (GA). 2014. ">WHO 2014</a>), and does not provide convincing evidence for any alternate regimen.  </p> <p>This review is largely based on studies conducted in areas of relatively high endemicity. It does not provide evidence as to the role of mass administration of antibiotics as communities approach elimination of trachoma as a public health problem.  </p> </section> <h3 class="title" id="CD001860-sec-0141">Implications for research</h3> <section id="CD001860-sec-0141"> <p>The WHO Alliance for the Global Elimination of Trachoma endorsed the donation of azithromycin for the treatment of trachoma, and as of July 2019, over 850 million doses donated by Pfizer Inc. had been distributed via the International Trachoma Initiative (ITI) since 1999. Locations that have not yet started azithromycin mass drug administration would enable community‐randomised trials to be conducted under operational conditions. Inequities are bound to exist in some settings at start‐up, when resources for antibiotic distribution are generally in limited supply. Allocating interventions randomly in these circumstances is reasonable, with roll‐out of the intervention to areas initially randomised to 'control' in later treatment rounds. Such an approach has been used in several of the trials included in this review. Trials are required to determine optimal dosage intervals of azithromycin at various levels of endemicity, test the most appropriate thresholds for starting and stopping mass treatment, determine minimum treatment coverage requirements, and to determine which subgroups could be treated at various stages of the pathway towards elimination. Potential strategies to evaluate could be selected on the basis of recent mathematical modelling work. Cost‐effectiveness per extra case cured should be one of the outcome measures. The adverse effects of azithromycin and emergence and persistence of resistance are also areas that should be addressed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001860-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001860-sec-0029"></div> <div class="table" id="CD001860-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic versus control for trachoma: individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotic versus control for trachoma: individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> people resident in a trachoma endemic area<br/> <b>Intervention:</b> antibiotics, including (oxy)tetracycline, doxycycline, sulfonamides<br/> <b>Comparison:</b> control (no treatment or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Active trachoma</b> </p> <p>Clinical assessment: active trachoma defined as TF, TI, or both<br/>   </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> <br/> (0.69 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1961<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b><br/> (552 to 712) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.74</b> <br/> (0.55 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1035<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>555 per 1000</b><br/> (413 to 750) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b> </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> <br/> (0.63 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b><br/> (315 to 520) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.25</b> <br/> (0.08 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/> (16 to 156) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>4 studies made no comment on adverse effects. </p> <p>3 studies noted no untoward reactions (sulfonamides) or only trivial reactions (tetracycline, sulfonamide). </p> <p>1 study of 155 students noted 3 adverse reactions to sulfonamide (severe purpura associated with marked thrombocytopenia, 2 cases of drug rash). </p> <p>1 study of 122 children noted anorexia, nausea, vomiting, or diarrhoea in 3 children. 2 of these children were receiving doxycycline, and the disturbances lasted only a single day in each child, in spite of continuing medication. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1961<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; three studies at high risk of attrition bias) and one level for serious inconsistency (risk ratios ranged from 0.40 to 1.02 and I<sup>2</sup> = 73%).<br/> <sup>2</sup>Downgraded one level for serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; two studies at high risk of attrition bias) and one level for serious inconsistency: risk ratios ranged from 0.50 to 1.05 and  I<sup>2</sup> = 90%). We did not additionally downgrade for imprecision, although the upper confidence interval was 1.00, as we felt that this imprecision probably reflects limitations in study design and inconsistency.<br/> <sup>3</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported; two studies at high risk of attrition bias) and one level for serious imprecision (95% CI 0.63 to 1.04 include null effect 1).<br/> <sup>4</sup>Downgraded two levels for very serious limitations in study design (only one small study with poorly reported methods of sequence generation and allocation concealment and which did not mask outcome assessment).<br/> <sup>5</sup>Downgraded one level for very serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; three studies at high risk of attrition bias) and one level for imprecision, as the studies were not large enough to assess rare adverse events.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001860-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral versus topical antibiotic for trachoma: individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Oral versus topical antibiotic for trachoma: individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> people resident in a trachoma endemic area<br/> <b>Intervention:</b> oral antibiotic, including azithromycin, doxycycline, sulfamethoxypyridazine, and sulfadimethoxine<br/> <b>Comparison:</b> topical antibiotic, including tetracycline and sulfafurazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical antibiotic</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Active trachoma</b> </p> <p>Clinical assessment: active trachoma defined as TF, TI, or both</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97 </b><br/> (0.81 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>953<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>582 per 1000</b><br/> (486 to 696) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> <br/> (0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>886<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b><br/> (375 to 575) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b> </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooled estimate due to high heterogeneity: <a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> RR 6.05 (95% CI 0.78, 46.95); <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> RR 0.57 (0.14, 2.30); <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> RR 1.30 (0.41, 4.11) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> RR 2.59 (95% CI 0.28, 23.88); <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> RR 0.50 (0.18, 1.43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>3 studies made no comment on adverse effects.</p> <p>1 study of 155 students noted 3 adverse reactions to sulfonamide (severe purpura associated with marked thrombocytopenia, 2 cases of drug rash). </p> <p>1 study of 194 people reported abdominal pain more often in azithromycin group (26% versus 16%, P = 0.09). Other effects: diarrhoea, vomiting, fever, headache, body pain were  similar between 2 study groups.  </p> <p>1 study of 60 people reported no serious adverse reactions and that both azithromycin and tetracycline were well tolerated.   </p> <p>1 study of 168 children noted that azithromycin was well tolerated and that only 2 children (of 125 treated) complained of nausea. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1583<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (only one study reported adequate methods for allocation concealment and masking of outcome assessment) and one level for inconsistency (study estimates ranged from 0.65 to 1.37 and I<sup>2</sup> = 63%).<br/> <sup>2</sup>Downgraded one level for serious limitations in study design (only one study reported adequate methods for allocation concealment and masking of outcome assessment) and one level for inconsistency (study estimates ranged from 0.66 to 1.15 and I<sup>2</sup> = 56%).<br/> <sup>3</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported, one study at high risk of attrition bias) and two levels for very serious inconsistency (see comment column in table).<br/> <sup>4</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported, one study at high risk of attrition bias); one level for serious inconsistency (see comment column in table); and one level for imprecision (only 16 events in total).<br/> <sup>5</sup>Downgraded one level for serious limitations in study design (none of the trials reported adequate methods of allocation concealment and masking of outcome assessment, and adverse effects were not consistently considered and reported) and one level for imprecision (individual studies were underpowered to assess rare effects).  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001860-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral azithromycin compared to control for trachoma: communities</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral azithromycin compared to control for trachoma: communities</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> communities in a trachoma endemic area<br/> <b>Intervention:</b> oral azithromycin<br/> <b>Comparison:</b> control (no treatment) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence (GRADE)<br/>  </b> </p> </td> <td align="left" class="table-header" colspan="0" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Active trachoma</b><br/> Clinical assessment: active trachoma defined as TF, TI, or both </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.58</b> </p> <p>(0.52 to 0.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1247<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <b>moderate</b><sup>1</sup><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="4" valign="top"> <p>One additional study reported data as median community prevalence. At 12 months, the median community prevalence of active trachoma was 9.3% in communities given one single dose of azithromycin (range 0 to 38.9%) and 8.2% in communities that had not been treated (range 0 to 52.9%). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>(52 to 65)</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> </p> <p>(156 to 195)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b><br/> Follow‐up: 3 months </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.36 </b><br/> (0.31 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2139</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <b>moderate</b><sup>2</sup><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/> (31 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (93 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was evidence of an increased risk of resistance of <i>S pneumoniae</i> , <i>S aureus</i> , and <i>E coli</i> to azithromycin, tetracycline, and clindamycin with risk ratios in the order of 5 at 12 months. No evidence to support increased resistance to penicillin or trimethoprim/sulfamethoxazole. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1354</p> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <b>high</b><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No serious adverse events reported. Azithromycin associated with reduced mortality in children. Main adverse effect of azithromycin (in approximately 10% of the population) was abdominal pain, vomiting, and nausea. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3069<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <b>high</b><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (medium/high risk) were based on prevalence estimates used as the basis for recommendations as set out in <a href="./references#CD001860-bbs2-0134" title="World Health Organization. Report of the 3rd global scientific meeting on trachoma. www.who.int/trachoma/resources/who_pbd_2.10/en/. ">WHO 2010</a>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious inconsistency.<br/> <sup>2</sup>Downgraded one level for serious inconsistency: I<sup>2</sup> = 79%. However, both study estimates were in the same direction 0.32 (0.26 , 0.40) and 0.49 (0.36 , 0.68). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001860-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral azithromycin compared to topical tetracycline for trachoma: communities</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Oral azithromycin compared to topical tetracycline for trachoma: communities</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> communities in a trachoma endemic area<br/> <b>Intervention:</b> oral azithromycin<br/> <b>Comparison:</b> topical tetracycline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical tetracycline</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Active trachoma</b><br/> Clinical assessment: active trachoma defined as TF, TI, or both </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.52 (95% CI 0.43, 0.64); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.16 (1.00, 1.36); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.76 (0.50, 1.15) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.74 (95% CI 0.61, 0.90); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.19 (1.02, 1.40); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.55 (0.40, 0.75) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocular <i>C trachomatis infection</i> </b><br/> Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5773<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.22 (95% CI 0.11, 0.44); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 0.68 (0.49, 0.95); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.51 (0.37, 0.70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5276<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.48 (95% CI 0.31, 0.74); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.01 (0.76, 1.35); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.62 (0.44, 0.87) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No comment on adverse effects in study reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (three cluster‐randomised trials, two of which only randomised two communities to oral/topical antibiotic; assessment of trachoma was not masked, but assessment of ocular infection was; recruitment bias not addressed and problems with incomplete outcome data; some attempt made to adjust for baseline imbalances) and one level for serious inconsistency (results were different in the different studies ‐ see comment column in table). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001860-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001860-sec-0030"></div> <section id="CD001860-sec-0031"> <h3 class="title" id="CD001860-sec-0031">Description of the condition</h3> <p>Trachoma is the world's leading infectious cause of blindness (<a href="./references#CD001860-bbs2-0136" title="World Health Organization. Trachoma. www.who.int/trachoma/disease/en/ (accessed 20 November 2018). ">WHO 2018</a>). In 2015, there were an estimated 398,000 people blind due to trachoma (80% uncertainty intervals 114,000 to 851,000) (<a href="./references#CD001860-bbs2-0106" title="FlaxmanSR , BourneRR , ResnikoffS , AcklandP , BraithwaiteT , CicinelliMV , et al. Global causes of blindness and distance vision impairment 1990‐2020: a systematic review and meta‐analysis. Lancet Global Health2017;5(12):e1221‐34. ">Flaxman 2017</a>). Trachoma is a disease of poverty and is associated with poor water supplies and sanitation (<a href="./references#CD001860-bbs2-0108" title="GarnJV , BoissonS , WillisR , BakhtiariA , Al‐KhatibT , AmerK , et al. Sanitation and water supply coverage thresholds associated with active trachoma: modeling cross‐sectional data from 13 countries. PLoS Neglected Tropical Diseases2018;12:e0006110. ">Garn 2018</a>). The age‐standardised all‐ages prevalence of blindness due to trachoma varies from 0% in most high‐income countries to 0.23% (0.07% to 0.42%) in East sub‐Saharan Africa and 0.19% (0.06% to 0.35%) in West sub‐Saharan Africa (<a href="./references#CD001860-bbs2-0106" title="FlaxmanSR , BourneRR , ResnikoffS , AcklandP , BraithwaiteT , CicinelliMV , et al. Global causes of blindness and distance vision impairment 1990‐2020: a systematic review and meta‐analysis. Lancet Global Health2017;5(12):e1221‐34. ">Flaxman 2017</a>). </p> <p>There are two phases of trachoma. In the first phase, most frequently seen in infancy and childhood, there are repeated rounds of conjunctivitis caused by the bacterium <i>Chlamydia trachomatis</i> . The conjunctivitis is characterised by the presence of follicles on the under surface of the upper eyelid and by vascular changes and is known as active trachoma. Active trachoma is associated with discharge from the eyes and nose that is particularly noticeable on the faces of children, but the active stage may also be asymptomatic in children and adults. When symptomatic, symptoms may persist for months after the infection is cleared. <i>C trachomatis</i> is thought to be transmitted from child to child and from child to mother and back to child through eye‐finger‐eye contacts, fomites, and via eye‐seeking flies. </p> <p>Repeated conjunctival infections over a number of years can lead to the second phase of disease, characterised by scarring and shortening of the upper eyelid. Ultimately, the lashes turn inwards to rub on the cornea, causing pain, corneal abrasions, and secondary infection. Treatment at this stage is surgery to reposition the eyelid margin. Blindness results from corneal opacification. The blinding phase affects women more commonly than men (<a href="./references#CD001860-bbs2-0098" title="CromwellEA , CourtrightP , KingJD , RotondoLA , NgondiJ , EmersonPM . The excess burden of trachomatous trichiasis in women: a systematic review and meta‐analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene2009;103(10):985‐92. ">Cromwell 2009</a>), and typically starts in adult life (<a href="./references#CD001860-bbs2-0096" title="BurtonMJ , MabeyDC . The global burden of trachoma: a review. PLoS Neglected Tropical Diseases2009;3:e460. ">Burton 2009</a>). </p> </section> <section id="CD001860-sec-0032"> <h3 class="title" id="CD001860-sec-0032">Description of the intervention</h3> <p>Active trachoma has been treated with antibiotics since the 1950s, and a variety of regimens have been used. The antibiotic can be applied directly to the conjunctiva (topical) or taken orally (systemic). Topically applied antibiotics are usually in the form of an ointment, and a variable amount is squeezed onto the inner surface of the lower eyelid. This route gives a high concentration of the antibiotic to the conjunctiva but a low dose to the nasopharynx, which is also a reservoir for the organism. Ointments may cause stinging eyes and temporary blurred vision, and they are difficult to apply to small children. </p> <p>Oral treatment gives a higher dose of antibiotic to sites of infection outside of the eye, but systemic antibiotics can cause various adverse effects in the person taking them. Bacteria anywhere in the body may also develop antibiotic resistance. As the currently recommended oral antibiotic regimen is a single, directly observed dose of azithromycin, as compared to six weeks of twice‐daily topical tetracycline, oral treatment is likely to have a higher compliance rate than a course of topical antibiotic. </p> <p>Efforts in trachoma control have used various antibiotic treatment regimens and have also been aimed at different subgroups within a trachoma endemic area. Examples of subgroups are: only those individuals with clinical signs of disease (detected actively or passively); active cases together with family contacts; or high‐risk groups including schoolchildren. Because many individuals harbour infection without demonstrating clinical signs, it has been suggested that trachoma elimination cannot be achieved by antibiotic treatment given only to subgroups of a trachoma endemic community (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0061" title="KamiyaS . Mass treatment of trachoma. American Journal of Ophthalmology1956;42:269‐83. ">Kamiya 1956</a>; <a href="./references#CD001860-bbs2-0126" title="SutterEE , BallardRC . Community participation in the control of trachoma in Gazankulu. Social Science and Medicine1983;17(22):1813‐7. ">Sutter 1983</a>). This led to the concept of community‐based interventions, where all residents of a community should receive treatment irrespective of disease status. </p> <p>The desired primary endpoint of any intervention against active disease is reduction of blindness, but this can only be demonstrated 20 to 30 years after the start of the intervention. The usual surrogate outcome measure in trachoma intervention trials is clinically active disease. In some trials a secondary endpoint is laboratory evidence of ocular <i>C trachomatis</i> infection. </p> </section> <section id="CD001860-sec-0033"> <h3 class="title" id="CD001860-sec-0033">Why it is important to do this review</h3> <p>International interest in trachoma was given a boost in 1996 when the World Health Organization (WHO) launched a new initiative for trachoma control, based on the 'SAFE' strategy, and in 1998 the 51st World Health Assembly passed a resolution on "Global elimination of blinding trachoma" (<a href="./references#CD001860-bbs2-0132" title="World Health Assembly. WHA51.11 Global elimination of blinding trachoma. www.who.int/blindness/causes/WHA51.11/en/ (accessed 22 November 2018). ">WHA 1998</a>). The components of the SAFE acronym are <b>S</b> urgery, <b>A</b> ntibiotics, <b>F</b> acial cleanliness, and <b>E</b>nvironmental improvement. Cochrane Reviews on surgery for trichiasis (<a href="./references#CD001860-bbs2-0097" title="BurtonM , HabtamuE , HoD , GowerEW . Interventions for trachoma trichiasis. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD004008.pub2] ">Burton 2015</a>), face washing (<a href="./references#CD001860-bbs2-0105" title="EjereH , AlhassanMB , RabiuM . Face washing promotion for preventing active trachoma. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003659.pub2] ">Ejere 2015</a>), and environmental sanitary interventions have also been completed (<a href="./references#CD001860-bbs2-0120" title="RabiuM , AlhassanMB , EjereHOD , EvansJR . Environmental sanitary interventions for preventing active trachoma. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004003.pub3] ">Rabiu 2012</a>). </p> <p>The WHO recommends the following antibiotic treatment for trachoma: either topical treatment of 1% tetracycline ointment to both eyes, twice daily for six weeks, or azithromycin, given as a single oral dose of 1 g in adults and 20 mg/kg of body weight in children (<a href="./references#CD001860-bbs2-0125" title="SolomonAW , ZondervanM , KuperH , BuchanJC , MabeyDC , FosterA . Trachoma Control: a Guide for Programme Managers. Geneva: World Health Organization, 2006. ">Solomon 2006</a>). </p> <p>This review was important to systematically evaluate the safety and effectiveness of these recommended treatment regimens. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001860-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001860-sec-0034"></div> <p>To assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma (primary objective), <i>Chlamydia trachomatis</i> infection of the conjunctiva, antibiotic resistance, and adverse effects (secondary objectives).  </p> <p>(1) What is the effect of antibiotic treatment of the individual on active trachoma and ocular <i>C trachomatis</i> infection? </p> <p> <ul id="CD001860-list-0001"> <li> <p>What is the effect of antibiotic treatment versus no treatment?</p> </li> <li> <p>What is the effect of oral versus topical antibiotic?</p> </li> <li> <p>What is the effect of oral azithromycin compared to topical tetracycline?</p> </li> </ul> </p> <p>(2) What is the effect of community treatment with antibiotics on the prevalence of active trachoma and ocular <i>C trachomatis</i> infection? </p> <p> <ul id="CD001860-list-0002"> <li> <p>What is the effect of mass administration of antibiotic compared to no treatment?</p> </li> <li> <p>What is the effect of mass administration of oral azithromycin versus topical tetracycline?</p> </li> <li> <p>What is the effect of annual versus different treatment frequencies?</p> </li> </ul> </p> <p>(3) What are the adverse effects of antibiotic treatment?</p> <p> <ul id="CD001860-list-0003"> <li> <p>What are the adverse effects at the individual level?</p> </li> <li> <p>What is the effect of mass administration of oral azithromycin or topical tetracycline on resistance in (i) <i>C trachomatis</i> and (ii) other bacteria? </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001860-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001860-sec-0035"></div> <section id="CD001860-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001860-sec-0037"> <h4 class="title">Types of studies</h4> <p>This review includes only randomised controlled trials (RCTs) of antibiotic treatment for active trachoma. We included clinical and community‐based trials. In clinical trials, the unit of randomisation was the individual with active trachoma, and outcomes were reported at an individual level. In community‐based trials, the unit of randomisation was a community, in which some individuals had active trachoma, and outcomes may have been reported at an individual or a community level. </p> </section> <section id="CD001860-sec-0038"> <h4 class="title">Types of participants</h4> <p>Participants in the trials were people who were usually resident in a trachoma endemic area. </p> </section> <section id="CD001860-sec-0039"> <h4 class="title">Types of interventions</h4> <p>We included trials in which the interventions were:</p> <p> <ol id="CD001860-list-0004"> <li> <p>topical or oral administration of an antibiotic at any dose or frequency compared to placebo or no treatment; </p> </li> <li> <p>topical administration of an antibiotic at any dose or frequency compared to oral administration of an antibiotic at any dose or frequency. </p> </li> </ol> </p> <p>We excluded studies if the antibiotic was combined with an environmental or educational intervention unless this component was used uniformly across the trial, and only the antibiotic treatment varied in the different groups. </p> <p>We also included studies addressing different dosing strategies in the population. </p> </section> <section id="CD001860-sec-0040"> <h4 class="title">Types of outcome measures</h4> <p>We measured outcomes at three, 12, and 24 months after the start of treatment. Three months was the time at which the maximum effect on active trachoma was expected, given that clinical signs take several months to resolve after the clearance of infection (<a href="./references#CD001860-bbs2-0112" title="GrasslyNC , WardME , FerrisS , MabeyDC , BaileyRL . The natural history of trachoma infection and disease in a Gambian cohort with frequent follow‐up. PLoS Neglected Tropical Diseases2008;2:e341. ">Grassly 2008</a>). We selected 12 months to represent the period during which recurrence of infection or relapse would most likely occur, and 24 months to reflect the expected long‐term result of one course of treatment. A course of treatment may be a single or multiple doses of an oral antibiotic or interrupted applications of a topical antibiotic applied over six weeks to several months. </p> <p>In order to take into account the fact that studies may not have collected outcomes at these exact times, we defined the following ranges for each: </p> <p> <ul id="CD001860-list-0005"> <li> <p>three months, i.e. outcomes measured before six months;</p> </li> <li> <p>12 months, i.e. outcomes measured between six months and 18 months;</p> </li> <li> <p>24 months, i.e. outcomes measured after 18 months.</p> </li> </ul> </p> <p>If more than one outcome measurement in any of these follow‐up ranges was available, then we selected the nearest measurement to three, 12, or 24 months. </p> <section id="CD001860-sec-0041"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was <b>active trachoma</b>. There are five main trachoma grading scales (<a href="./references#CD001860-bbs2-0101" title="DawsonCR , JonesBR , DarougarS . Blinding and non‐blinding trachoma: assessment of intensity of upper tarsal inflammatory disease and disabling lesions. Bulletin of the World Health Organization1975;52(3):279‐82. ">Dawson 1975a</a>; <a href="./references#CD001860-bbs2-0102" title="DawsonCR , JonesBR , TarizzoML . A Guide to Trachoma Control. Geneva: World Health Organization, 1981. ">Dawson 1981a</a>; <a href="./references#CD001860-bbs2-0118" title="MacCallanAF . Trachoma. London: Butterworth, 1936. ">MacCallan 1936</a>; <a href="./references#CD001860-bbs2-0128" title="ThyleforsB , DawsonCR , JonesBR , WestSK , TaylorHR . A simple system for the assessment of trachoma and its complications. Bulletin of the World Health Organization1987;65(4):477‐83. ">Thylefors 1987</a>; <a href="./references#CD001860-bbs2-0133" title="World Health Organization. Criteria of clinical diagnosis. Expert Committee in Trachoma. 1962; Vol. Third report:8. ">WHO 1962</a>). All these scales except for MacCallan quantify the number of follicles and the degree of vascular engorgement of the under surface of the upper eyelid as seen with low magnification (usually x 2.5). The Dawson scales subdivide the follicular and papillary activity as F 0 to 3 and P 0 to 3. The Thylefors scale is a simplified version defining active trachoma by the grades TF (trachomatous inflammation‐follicular) and TI (trachomatous inflammation‐intense). The MacCallan scale is not directly comparable with the other scales, as scarring is included as an indicator of active disease. The four more recent scales are broadly comparable. A minor inconsistency between them is that Dawson's F1 is defined as five or fewer follicles in zones two and three, and F2 as "more than 5 follicles in zones 2 and 3 together, but less than 5 in zone 3"; whereas TF is five or more follicles in zones two and three. This means that the divisions between F1 and F2 and 'not TF' and TF do not quite coincide. </p> <p>In this review we defined the absence of active trachoma as:</p> <p> <ul id="CD001860-list-0006"> <li> <p>not TF and not TI (Thylefors scale);</p> </li> <li> <p>(P0 or P1 or P2) AND (F0 or F1) (WHO and Dawson scales).</p> </li> </ul> </p> <p>We defined active trachoma as TF, TI, or both, in the Thylefors scale; or any other grade for P or F in the WHO or Dawson scales.  </p> </section> <section id="CD001860-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcome for this review was <b>a positive test for <i>C trachomatis</i> infection</b>. A variety of tests have been used to demonstrate presence of the pathogen. Historically, staining of conjunctival cells to show inclusion bodies was the first method of identifying infection. This was followed by culture of the organism, which was time consuming and lacking in sensitivity. The demonstration of antigen by various antibody staining methods followed, and finally identification of chlamydial DNA by various nucleic acid amplification methods. The tests, in order of increasing sensitivity, are: </p> <p> <ul id="CD001860-list-0007"> <li> <p>culture by <i>C trachomatis</i> isolation in eggs or tissue culture; </p> </li> <li> <p>staining of conjunctival smears with Giemsa or iodine;</p> </li> <li> <p>direct fluorescent antibody cytology;</p> </li> <li> <p>indirect enzyme immunoassay;</p> </li> <li> <p>nucleic acid test (NAT);</p> </li> <li> <p>nucleic acid amplification tests (NAAT).</p> </li> </ul> </p> <p>For the current update we defined an additional secondary outcome: <b>resistance: proportion of samples showing evidence of resistance to antibiotic</b> in (i) <i>C trachomatis</i> and (ii) other bacteria. We considered any measure of resistance reported in the included studies. This included genotypic and phenotypic measures for all organisms and drug classes. We focused on the proportion of samples that were resistant, but also collected data, where available, on the proportion of isolates that were resistant. </p> <section id="CD001860-sec-0043"> <h6 class="title">Adverse effects</h6> <p>We recorded all adverse effects reported in the included studies.</p> </section> </section> </section> </section> <section id="CD001860-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001860-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following electronic databases for randomised controlled trials and controlled clinical trials. There were no restrictions on language or year of publication. The electronic databases were last searched on 4 January 2019. </p> <p> <ul id="CD001860-list-0008"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 1) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 4 January 2019) (<a href="./appendices#CD001860-sec-0145">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 4 January 2019) (<a href="./appendices#CD001860-sec-0146">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 4 January 2019) (<a href="./appendices#CD001860-sec-0147">Appendix 3</a>). </p> </li> <li> <p>International Standard Randomised Controlled Trial Number (ISRCTN) registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 4 January 2019) (<a href="./appendices#CD001860-sec-0148">Appendix 4</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 4 January 2019) (<a href="./appendices#CD001860-sec-0149">Appendix 5</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 4 January 2019) (<a href="./appendices#CD001860-sec-0150">Appendix 6</a>). </p> </li> </ul> </p> </section> <section id="CD001860-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We used the Science Citation Index to search for articles that cited the included studies. We searched the reference lists of included articles for any other potentially relevant studies. For previous versions of this review, we also contacted experts in the field, either directly or through the membership of the WHO workshops, requesting information on unpublished trials. We did not do this for the current update, however we did contact individual trialists for more information. </p> </section> </section> <section id="CD001860-sec-0047"> <h3 class="title" id="CD001860-sec-0047">Data collection and analysis</h3> <section id="CD001860-sec-0048"> <h4 class="title">Selection of studies</h4> <p>For the first publication of this review (<a href="./references#CD001860-bbs2-0139" title="MabeyD , Fraser‐HurtN , PowellC . Antibiotics for trachoma. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001860.pub2] ">Mabey 2005</a>), one review author assessed the titles identified from the initial searches and selected all titles that made reference to treatment for trachoma. For subsequent updates (<a href="./references#CD001860-bbs2-0137" title="EvansJR , SolomonAW . Antibiotics for trachoma. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD001860.pub3] ">Evans 2011</a> and current update), two review authors screened the search results. The searches also found references to genital <i>C trachomatis</i> infections and to laboratory tests on <i>C trachomatis</i>. We excluded titles that clearly referred to either of these groups at the first screening. Two review authors independently reviewed the full texts of all potentially relevant papers and assessed them according to the <a href="#CD001860-sec-0036">Criteria for considering studies for this review</a>. </p> </section> <section id="CD001860-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data. Any discrepancies were resolved before data were entered into Review Manager 5 (<a href="./references#CD001860-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">Review Manager 2008</a>). </p> <p>For the 2011 review update, JE checked the original data collection and entry. The changes that were made are summarised in <a href="./appendices#CD001860-sec-0151">Appendix 7</a>. For the newly identified trials, two review authors (JE, AWS) independently extracted data, resolving any discrepancies by discussion. Data were entered by both review authors onto two spreadsheets and cross‐checked. Data were cut and pasted into RevMan from the spreadsheet (JE). For the current update, the process was repeated by JE/EHE using updated Review Manager 5 (RevMan 5) software (<a href="./references#CD001860-bbs2-0122" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD001860-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias using Cochrane's 'Risk of bias' assessment tool as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001860-bbs2-0114" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We assessed the extent to which bias could have been introduced in the following aspects of study design and execution: sequence generation, allocation concealment, blinding (masking), incomplete outcome data, and selective outcome reporting. We considered two additional criteria for cluster‐randomised trials: recruitment bias and baseline imbalances (<a href="./references#CD001860-bbs2-0113" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Two review authors (JE/AWS (2011), JE/EHE (2019)) independently assessed risk of bias, compared results, and resolved any discrepancies by discussion. </p> </section> <section id="CD001860-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome for the review was active trachoma, and the secondary outcomes were ocular <i>C trachomatis</i> infection and antibiotic resistance. These are dichotomous (adverse) outcomes, and our preferred effect measure was the risk ratio. </p> </section> <section id="CD001860-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>This review includes trials in which individuals were randomly allocated to treatment and trials in which communities were the unit of allocation (cluster‐randomised trials). A correct analysis of cluster‐randomised trials includes an adjustment for the fact that people within a cluster tend to be more similar to each other than to people from other clusters (i.e. the observations are not independent). The effect of cluster‐randomisation is to increase the size of standard errors and hence widen the confidence intervals compared with a study of the same size using individual participant randomisation (<a href="./references#CD001860-bbs2-0104" title="DonnerA . An empirical study of cluster randomization. International Journal of Epidemiology1982;11(3):283‐6. ">Donner 1982</a>). </p> <p>Our preferred method of analysis of cluster‐randomised studies was as follows: for those studies that reported the effect measure using an analysis that properly accounted for the cluster design, we planned to enter and pool data from different studies using the generic‐inverse variance method in RevMan 5. However, we were aware that cluster‐randomised trials are not always analysed and reported appropriately. We planned that for those studies that did not report such an effect measure, we would perform an approximate analysis (<a href="./references#CD001860-bbs2-0113" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), as follows: </p> <p> <ul id="CD001860-list-0009"> <li> <p>calculate a 'design effect' of 1 + (M − 1) ICC (where ICC = intracluster correlation coefficient and M = average cluster size); </p> </li> <li> <p>multiply the standard error of an analysis at the individual level by the square root of the design effect. </p> </li> </ul> </p> <p>Estimates from the literature suggest that the ICC can vary from 0.05 to 0.2 (<a href="./references#CD001860-bbs2-0116" title="KatzJ , ZegerSL , TielschJM . Village and household clustering of xerophthalmia and trachoma. International Journal of Epidemiology1988;17(4):865‐9. ">Katz 1988</a>; <a href="./references#CD001860-bbs2-0130" title="WestSK , MunozB , TurnerVM , MmbagaBB , TaylorHR . The epidemiology of trachoma in central Tanzania. International Journal of Epidemiology1991;20(4):1088‐92. ">West 1991</a>). We planned sensitivity analyses using ICC estimates of 0.05, 0.1 and 0.2. </p> </section> <section id="CD001860-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>The clinical need to change or discontinue antibiotic therapy (for an individual undergoing treatment for a single episode of infection of disease, or a community undergoing a single round of mass treatment) is likely to be rare. This reduces the potential problems associated with performing the analysis on an intention‐to‐treat basis. More serious problems may arise from losses to follow‐up and non‐compliance. Some of the trials have been done in largely transient populations in which losses to follow‐up rapidly accumulate as people move on. Such losses were assumed to be independent of the outcome measures, therefore we did not exclude studies on this basis. </p> </section> <section id="CD001860-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by considering clinical and study design differences between trials and by examining the forest plots. We also considered statistical measures of heterogeneity such as the χ<sup>2</sup> test and I<sup>2</sup> statistic. </p> </section> <section id="CD001860-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>As less than 10 trials were included in the meta‐analyses in this version of the review, we did not assess publication bias. In future updates that include more trials, we will assess the possibility of small‐study effects, including publication bias, using a funnel plot (plotting the risk ratio along the x‐axis versus standard error along the y‐axis). </p> <p>We included all trials irrespective of the language of publication, however we cannot exclude the possibility that negative trials have been published in less accessible journals (see publication bias above). </p> <p>We did not find any evidence of multiple (duplicate) reporting publication bias. Data from one of our included trials, <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>, were published twice, with ocular <i>C trachomatis</i> infection being the focus of one publication and active trachoma the focus of the other, but the relationship of the data was clear from the publications. </p> </section> <section id="CD001860-sec-0056"> <h4 class="title">Data synthesis</h4> <p>In the original review, the review authors pooled outcomes from community‐based trials in which non‐affected and affected cases were treated with outcomes from individual‐based trials in which only affected cases were treated. The original protocol planned but did not carry out a sensitivity analysis to determine the effect of using only data from cases that were active at baseline. </p> <p>In the updates we considered these community‐based and individually randomised trials separately, as we believed that they were asking different questions and were likely to be estimating different treatment effects. The individually randomised studies address the question: what is the effect of antibiotic treatment on individuals? The cluster‐randomised trials address the question: what is the effect of antibiotic treatment on communities? The effect of treatment in individuals in treated communities may be different because as well as the individual‐level effect, there may be an additional impact via reduction in transmission. The following two objectives were identified. </p> <p>Where appropriate, data were pooled using a random‐effects model. We used a fixed‐effect model if there were three or fewer trials. In cases where there was substantial heterogeneity or inconsistency, that is the individual study estimates were different sides of the null line and/or confidence intervals did not overlap, with corresponding high levels of I<sup>2</sup>, we did not pool the results. </p> </section> <section id="CD001860-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered type of antibiotic (oral or topical) to be a potential source of clinical heterogeneity. This subgroup analysis was not specified explicitly but was implied in the objectives of the original protocol, which were to consider oral and topical antibiotics separately, in particular oral azithromycin and topical tetracycline. A further subgroup analysis considered just those trials in which communities were randomised to oral azithromycin, topical tetracycline, or both, where the antibiotic was administered using regimens consistent with WHO guidelines current in 2010, compared either to each other, placebo, or no treatment. </p> </section> <section id="CD001860-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>As set out above in the <a href="#CD001860-sec-0052">Unit of analysis issues</a> section, we considered the possible effect of assumptions about the size of the intracluster correlation coefficient (ICC) on the results. </p> <section id="CD001860-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>'Summary of findings' tables were introduced in the current update following new Cochrane guidance. As such, these tables are post hoc, but as fewer than seven outcomes were specified in this review, and we focused on the key comparisons in individuals and communities, there were no significant judgements that may have been influenced by our knowledge of the data in the preparation of these tables. We graded the certainty of the evidence for the comparisons and outcomes included in the 'Summary of findings' tables using the GRADE approach (<a href="./references#CD001860-bbs2-0123" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). We considered risk of bias in the studies contributing data, consistency of effects, precision of the effect estimate, directness of the evidence, and possibility of publication bias when grading the evidence. The initial assessment was done by JE, and this was checked by co‐authors. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001860-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001860-sec-0060"></div> <section id="CD001860-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD001860-sec-0062"> <h4 class="title">Results of the search</h4> <p><i><b>2011 version</b> </i><br/> The previous edition of this review published in 2011 included 22 studies. Fourteen of these studies were individually randomised, and a further eight were cluster‐randomised. </p> <p><i><b>2019 update</b> </i><br/> The searches run in January 2019 yielded a further 1406 records (<a href="#CD001860-fig-0001">Figure 1</a>). After removal of 301 duplicates, the Cochrane Information Specialist screened the remaining 1105 records and removed 839 references that were not relevant to the scope of the review. We screened the remaining 266 references and obtained 51 full‐text reports for further assessment. We identified 27 reports of four new cluster‐randomised studies (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>). The searches identified three new reports for the <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> study and nine new reports for the <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> study. The total number of included studies was 26; see <a href="./references#CD001860-sec-0166" title="">Characteristics of included studies</a> for further details. </p> <div class="figure" id="CD001860-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We will assess two ongoing studies for potential inclusion when data become available (<a href="./references#CD001860-bbs2-0091" title="NCT03523156 . Trachoma Elimination Study by Focused Antibiotic (TESFA). clinicaltrials.gov/ct2/show/NCT03523156 (first received 14 May 2018). ">NCT03523156</a>; <a href="./references#CD001860-bbs2-0092" title="WondimkunSA , TadesseZ , CallahanK , EmersonPM , GebeyehuW , FreemanMC , et al. Sanitation, water and instruction in face‐washing for trachoma (SWIFT): the cluster‐randomized controlled trial's protocol and rationale. American Journal of Tropical Medicine and Hygiene2017;97(5 Suppl 1):185. ">SWIFT 2017</a>), and one study by <a href="./references#CD001860-bbs2-0090" title="LastA , CassamaE , BojangE , NabicassaM , BurrS , ThompsonK , et al. Trachoma elimination in an endemic island setting in West Africa: are two doses of oral azithromycin better than one?. American Journal of Tropical Medicine and Hygiene2015;93(Suppl 4):403‐4. ">Last 2015</a> is awaiting classification. </p> <p>We excluded nine reports of the following nine studies: <a href="./references#CD001860-bbs2-0036" title="CoulibalyYI , DickoI , KeitaM , KeitaMM , DoumbiaM , DaouA , et al. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. PLoS Neglected Tropical Diseases2013;7(5):e2221. ">Coulibaly 2013</a>; <a href="./references#CD001860-bbs2-0066" title="KeenanJD , BaileyRL , WestSK , ArzikaAM , HartJ , WeaverJ , et al. Azithromycin to reduce childhood mortality in sub‐Saharan Africa. New England Journal of Medicine2018;378:1583‐92. ">MORDOR 2018</a>; <a href="./references#CD001860-bbs2-0068" title="NCT00286026 . Azithromycin in Control of Trachoma II. clinicaltrials.gov/ct2/show/NCT00286026 (first received 2 February 2006). ">NCT00286026</a>; <a href="./references#CD001860-bbs2-0069" title="NCT00347607 . Study of three alternatives for mass treatment in trachoma villages of Tanzania. clinicaltrials.gov/ct2/show/NCT00347607 (first received 4 July 2006). ">NCT00347607</a>; <a href="./references#CD001860-bbs2-0070" title="NCT00347776 . Study of azithromycin to prevent recurrent trichiasis following surgery in Ethiopia (STAR). clinicaltrials.gov/ct2/show/NCT00347776 (first received 4 July 2006). ">NCT00347776</a>; <a href="./references#CD001860-bbs2-0071" title="NCT01178762 . The effect of oral azithromycin in the treatment of chlamydial conjunctivitis. clinicaltrials.gov/ct2/show/NCT01178762 (first received 10 August 2010). ">NCT01178762</a>; <a href="./references#CD001860-bbs2-0072" title="NCT01767506 . A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial (ASANTE). clinicaltrials.gov/ct2/show/NCT01767506 (first received 14 January 2013). ">NCT01767506</a>; <a href="./references#CD001860-bbs2-0073" title="NCT02211729 . A trial of seasonal malaria chemoprevention plus azithromycin in African children (SMCAZ). clinicaltrials.gov/ct2/show/results/NCT02211729 (first received 7 August 2014). ">NCT02211729</a>; <a href="./references#CD001860-bbs2-0081" title="SchachterleSE , MtoveG , LevensJP , ClemensE , ShiL , RajA , et al. Short‐term malaria reduction by single‐dose azithromycin during mass drug administration for trachoma, Tanzania. Emerging Infectious Diseases2014;20(6):941‐9. ">Schachterle 2014</a>. The total number of excluded studies is 63; see <a href="./references#CD001860-sec-0167" title="">Characteristics of excluded studies</a> for further details. </p> </section> <section id="CD001860-sec-0063"> <h4 class="title">Included studies</h4> <section id="CD001860-sec-0064"> <h5 class="title">Individually randomised studies</h5> <p>Fourteen individually randomised studies are included in the review (<a href="#CD001860-tbl-0005">Table 1</a>). </p> <div class="table" id="CD001860-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individually randomised studies: participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sex</b> </p> <p><b>% male</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma or "undetermined case"<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months to 60 years<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51%<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months to 10 years<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guinea and Pakistan<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐school</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38% </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian reservation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian reservation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian boarding school)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 to 20 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian boarding school)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia (Aboriginal children)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>641</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary school age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> and <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> were reported in the same paper. </p> </div> </div> <section id="CD001860-sec-0065"> <h6 class="title">Types of participants</h6> <p>These 14 studies took place in the following countries (according to WHO region) (one study, <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>, was conducted in two regions). </p> <section id="CD001860-sec-0066"> <p><b>African Region</b></p> <p> <ul id="CD001860-list-0010"> <li> <p>The Gambia (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>) </p> </li> <li> <p>Guinea (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0067"> <p><b>Eastern Mediterranean Region</b></p> <p> <ul id="CD001860-list-0011"> <li> <p>Egypt (<a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>) </p> </li> <li> <p>Iran (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>) </p> </li> <li> <p>Pakistan (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>) </p> </li> <li> <p>Saudi Arabia (<a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0068"> <p><b>Region of the Americas</b></p> <p> <ul id="CD001860-list-0012"> <li> <p>USA (<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>; <a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0069"> <p><b>South‐East Asian Region</b></p> <p> <ul id="CD001860-list-0013"> <li> <p>India (<a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0070"> <p><b>Western Pacific Region</b></p> <p> <ul id="CD001860-list-0014"> <li> <p>Australia (<a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a>) </p> </li> <li> <p>Taiwan (<a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>) </p> </li> </ul> </p> <p>The participants in these studies had active trachoma. The number of participants randomised ranged from 29, in <a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>, to 670, in <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>. Almost all of the studies enrolled children and/or young people (21 years or younger) only, with the exception of <a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>, which had a wider age range (9 months to 60 years). Not all studies reported the proportion of males and females, but in those that did there were approximately equal proportions. Participants in the studies in USA and Australia were from Indigenous communities (Native American and Aboriginal, respectively). </p> </section> </section> <section id="CD001860-sec-0071"> <h6 class="title">Types of interventions</h6> <p><a href="#CD001860-tbl-0006">Table 2</a> summarises the comparisons addressed in these studies. </p> <div class="table" id="CD001860-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Individually randomised studies: comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Studies with a no‐treatment, placebo, or inactive treatment comparator group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline derivative GS2989 (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once every school day for 11 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 7 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vitamin pills</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 6 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>daily for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once a month for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 4.0 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week up to 28 doses in 40 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week up to 28 doses in 40 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfafurazole (topical) + sulfadimethoxine (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15%/100 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days every month for 5 months/bi‐weekly for 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days every month for 5 months/bi‐weekly for 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; </p> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trisulfapyrimidines (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 g/day (in 3 doses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 consecutive days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral versus topical antibiotic</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once or weekly for 3 weeks or monthly for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline/polymyxin + oral placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline 1%/polymyxin 10,000 units/gram</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 28 days for 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sulfamethoxypyridazine (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 g</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 times daily on 5 consecutive days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>**** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 2 days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Also compared to oxytetracycline (Terramycin) once every school day for 11 weeks.<br/> **Also compared to doxycycline (oral) 5 mg/kg single dose every month for 12 months.<br/> ***Also compared to sulfadimethoxine (oral) 100 mg/kg bi‐weekly or weekly dose for 5 months and sulfafurazole (topical) 15% twice daily for 5 consecutive days, every month for 5 months.<br/> ****Also compared to azithromycin (topical) 1.5% twice daily for 3 days. </p> </div> </div> <p>Nine studies compared antibiotic with a no‐treatment or placebo arm. These antibiotics were: </p> <p> <ul id="CD001860-list-0015"> <li> <p>tetracycline or oxytetracycline applied topically (<a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a>; <a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>); </p> </li> <li> <p>oral tetracycline (<a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a>); </p> </li> <li> <p>doxycycline (<a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>); </p> </li> <li> <p>sulfonamides (<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>; <a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>). </p> </li> </ul> </p> <p>Four studies compared oral azithromycin with topical tetracycline (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>). </p> <p>One study compared topical azithromycin with oral azithromycin (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>). </p> <p>Azithromycin was usually given as a single dose of 20 mg/kg up to 1 g (for adults). Topical tetracycline was usually the 1% dose, although there was some variation in treatment schedules. In general, the application of topical tetracycline was supervised, or applied by personnel in the research team. The exceptions were <a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> and <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>, where the ointment was administered by carers and was not supervised.   </p> </section> <section id="CD001860-sec-0072"> <h6 class="title">Types of outcome measures</h6> <p>Reporting of the two main outcome measures for this review is presented in <a href="#CD001860-tbl-0007">Table 3</a>. </p> <div class="table" id="CD001860-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Individually randomised studies: outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Active trachoma</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Ocular infection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Classification scheme</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laboratory assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO 1962</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (26 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDEIA amplified enzyme‐linked immunosorbent assay (Dako) for genus‐specific lypopolysaccharide antigen </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (26 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (2 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival swab analysed using PCR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modification of Dawson 1975</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs followed by culture in irradiated McCoy cells</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacCallan 1936</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacCallan 1936</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival specimens; slides stained with direct fluorescent antibody for chlamydial elementary bodies </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thygeson 1960</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1969</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFAT on scrapings of upper tarsal conjunctival epithelium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 1 follicle or some papillary hypertrophy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO 1962</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival scrapings for inclusion bodies/cells/organisms/mucus; IFAT for free elementary bodies </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified McCallan classification</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IFAT: immunofluorescence antibody test<br/> PCR: polymerase chain reaction </p> <p>*Followed up to three years.</p> </div> </div> <p>All studies provided data at around three months (range two to five months). Six studies had longer follow‐up, ranging from six months (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>), and 12 months (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>) to three years (<a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>). </p> <p>All 14 individually randomised studies reported active trachoma at follow‐up. A variety of classification schemes were used for active trachoma. The majority of studies used one of the scales described in <a href="#CD001860-sec-0040">Types of outcome measures</a>. </p> <p> <ul id="CD001860-list-0016"> <li> <p>MacCallan 1936 (<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>; <a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>) </p> </li> <li> <p>WHO 1962 (<a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a>; <a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>) </p> </li> <li> <p>Dawson 1975 (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>) </p> </li> <li> <p>Dawson 1981 (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>) </p> </li> <li> <p>Thylefors 1987 (<a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>; <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>) </p> </li> </ul> </p> <p>Three studies used different classifications, but these were likely to have been based on a similar assessment (<a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>; <a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>; <a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a>). The trachoma grading scales used after 1962 do not have scarring as a feature of active trachoma, and so the underlying principles in the grades are more or less equivalent in all of the studies, using only the presence of follicles and papillae for diagnosis of active disease. </p> <p>Six of the 14 studies reported assessment of ocular infection (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>; <a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>; <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>), but comparative data on ocular infection between intervention groups were not reported by <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>. </p> <p>None of the studies considered resistance as an outcome. Adverse effects were reported inconsistently. </p> </section> </section> <section id="CD001860-sec-0073"> <h5 class="title">Cluster‐randomised studies</h5> <p>Twelve community‐based studies are included in the review (<a href="#CD001860-tbl-0008">Table 4</a>). </p> <div class="table" id="CD001860-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Cluster‐randomised studies: participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Inclusion criteria: communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Inclusion criteria: people</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of communities randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sex % male</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Endemicity</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Children</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages: no active trachoma (64%);<br/> mild follicular inflammatory (F1, P1, P2) (16%); follicular trachoma (F2, F3) (14%); severe inflammatory trachoma (P3) (6%)<br/> Prevalence of ocular infection (LCR‐positive) (36%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3261</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages: no active trachoma (47%); mild follicular inflammatory (F1, P1, P2) (22%); follicular trachoma (F2, F3) (15%); severe inflammatory trachoma (P3) (16%)<br/> Prevalence of ocular infection (LCR‐positive) (19%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (pair‐matched)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1753</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma among 0 to 9 year olds (36%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No active trachoma (57%); mild follicular inflammatory (F1, P1, P2) (27%); follicular trachoma (F2, F3) (9%); severe inflammatory trachoma (P3) (7%)<br/> Prevalence of ocular infection (LCR‐positive) (36%)<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vietnam</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>randomly selected from Thanh Hoa Province</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community older than 6 months was assessed for trachoma and people with trachoma and their household members treated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1851</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months or older</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma: <br/> 5 to 15 years (6%)<br/> less than 5 years (2%)<br/> <br/> Prevalence of <i>C trachomatis</i> infection:   <br/> 5 to 15 years (16%)<br/> less than 5 years (17%)<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma: <br/> 15 years and above (8%)<br/> <br/> Prevalence of <i>C trachomatis</i> infection: <br/> 15 years and above (8%)<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 15% prevalence of active trachoma in children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average age 18 to 19 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection (all ages) (7%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>population between 250 and 600 and prevalence of 10% or more of active trachoma in children aged 0 to 60 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children aged 0 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of ocular <i>C trachomatis</i> infection in children aged 5 years or younger (approximately 20%)<br/> <br/> Prevalence of TF in children aged 5 years or younger (25% to 30%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of TF in people aged 15 years or older (approximately 1%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>less than 5000 people with an estimated active trachoma prevalence of between 20% and 50% for mesoendemic communities and less than 20% for hypoendemic communities </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children aged 0 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% to 52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged less than 5 years ranged from 18% to 25%.<br/> <br/> Prevalence of TF in children aged less than 5 years was 30%. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection (all ages) (6%)<br/> <br/> Prevalence of TF (all ages) (12%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma prevalence greater than 5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children 5 years or less</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged 5 years or younger was 1%.<br/> <br/> Prevalence of TF in children aged 5 years or younger was 6%. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mali</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2 with interventions relevant to this review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma ranged from 15% to 22% (all ages).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all subkebeles (geographical unit with approximately 1400 people) in the study region that were less than<br/> a 3‐hour walk from the farthest point that could be reached with a 4‐wheel drive vehicle </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66,404</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel group of children and adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜51%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged less than 10 years ranged from 8% to 62% (mean approximately 40%). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in people aged 10 years or older ranged from 2% to 28% (mean approximately 15%).<br/> <br/> Prevalence of active trachoma (all ages) was between 69% and 77%. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>random sample of peasant associations (standardised administrative unit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5410</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel groups of children aged 1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged 1 to 5 years ranged from 31% to 65% (mean approximately 43%). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not been treated with azithromycin since 2009 and were predicted from prior prevalence surveys to have TF between 5 and 9.9% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not clearly stated but assumed to be everyone in community apart from pregnant women and children under 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months or older, only sample of 20 children aged 1 to 9 years assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48% (in children assessed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Prevalence of C<i>trachomatis</i> infection in children aged 1 to 9 years ranged from 0 to 33%, median 0%.<br/> <br/> Prevalence of TF in children aged 1 to 9 years ranged from 0 to 62%, median 5% </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>.‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LCR: ligase chain reaction <br/> TF: trachomatous inflammation–follicular </p> </div> </div> <section id="CD001860-sec-0074"> <h6 class="title">Types of participants</h6> <p>These 12 studies took place in the following countries (according to WHO region).</p> <section id="CD001860-sec-0075"> <p><b>African Region</b></p> <p> <ul id="CD001860-list-0017"> <li> <p>The Gambia (<a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>) </p> </li> <li> <p>Ethiopia (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>) </p> </li> <li> <p>Niger (<a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>; <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>) </p> </li> <li> <p>Mali (<a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>) </p> </li> <li> <p>Tanzania (<a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0076"> <p><b>Eastern Mediterranean Region</b></p> <p> <ul id="CD001860-list-0018"> <li> <p>Egypt (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>) </p> </li> </ul> </p> </section> <section id="CD001860-sec-0077"> <p><b>Western Pacific Region</b></p> <p> <ul id="CD001860-list-0019"> <li> <p>Vietnam (<a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>) </p> </li> </ul> </p> <p>The inclusion criteria for communities were not always clearly specified in these studies, and varied where they were specified. Some studies randomly selected communities in specific regions (<a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>); some studies specified a cut‐point in terms of prevalence of active trachoma between 5% and 20% (<a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>; <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>); one study included communities that had not received azithromycin since 2009 with an estimated prevalence of active trachoma between 5% and less than 10% (<a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>); and others used logistical considerations (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>). </p> <p>All the studies (except <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>) evaluated some form of mass drug administration and therefore included everyone present in the communities. The evaluation of the outcome was often done on a random sample of children and adults, termed a "sentinel" sample. Where sex was reported, approximately 50% of the population were male. </p> <p>Most studies were conducted in trachoma endemic areas with high levels of infection and clinical disease, particularly in children. The exceptions were <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>, <a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>, and <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>, where active trachoma and ocular infection were less than 20%.  </p> </section> </section> <section id="CD001860-sec-0078"> <h6 class="title">Types of interventions</h6> <p><a href="#CD001860-tbl-0009">Table 5</a> summarises the comparisons addressed in the 12 cluster‐randomised studies. Almost all of these studies evaluated mass drug administration with azithromycin at 20 mg/kg up to 1 g for adults. <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> assessed topical tetracycline 1%. <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> only treated people with active trachoma and their household members. </p> <div class="table" id="CD001860-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Cluster‐randomised studies: comparisons</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Studies with a no‐treatment or delayed‐treatment comparator group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline **</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once only; annually for 3 years; twice a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 3 months for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Studies of azithromycin versus tetracycline</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once a week for 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>**** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose at baseline and 12 months.</p> <p>Non‐index cases received tetracycline, and surgery offered where appropriate.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients with active trachoma received topical tetracycline and surgery offered where appropriate. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Studies of different frequencies of azithromycin</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>for 1 month (Day 0 and Day 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years (enhanced coverage)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years (standard coverage)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>;***** <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cessation rule</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Azithromycin was given as a single oral dose at 20 mg/kg up to 1 g (adults); tetracycline was given topically 1%.<br/> **One drop four times daily for seven days.<br/> ***Once a week for three weeks.<br/> ****Treatment of people with active trachoma and their household members only.<br/> *****Only children were treated twice yearly. </p> </div> </div> <p>Four studies compared antibiotic to no treatment, <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>, or delayed treatment (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>). </p> <p>Four studies compared azithromycin and topical tetracycline (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>; <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>). </p> <p>Six studies compared different strategies for mass drug administration:</p> <p> <ul id="CD001860-list-0020"> <li> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> compared azithromycin twice (one month apart) with a single dose of azithromycin; </p> </li> <li> <p>the three PRET studies compared enhanced coverage (&gt; 90%) with standard coverage (80% to 90%) (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>); </p> </li> <li> <p>three studies compared azithromycin twice a year for two or three years with azithromycin once a year for two or three years (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>), with only children being treated twice a year in <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; </p> </li> <li> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> and <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared azithromycin annually for three years with a cessation rule. </p> </li> </ul> </p> <p>Specific exclusion criteria were usually given for pregnant women, children younger than six months, or people with macrolide allergy. Other treatments offered included oral erythromycin or topical tetracycline. </p> </section> <section id="CD001860-sec-0079"> <h6 class="title">Types of outcome measures</h6> <p><a href="#CD001860-tbl-0010">Table 6</a> summarises the reporting of the main outcome measures for this review in these cluster‐randomised studies. Follow‐up ranged from six months, in <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>, to 42 months, in <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>, with most studies reporting at least to 12 months. Most studies used the classification of trachoma as set out in <a href="./references#CD001860-bbs2-0128" title="ThyleforsB , DawsonCR , JonesBR , WestSK , TaylorHR . A simple system for the assessment of trachoma and its complications. Bulletin of the World Health Organization1987;65(4):477‐83. ">Thylefors 1987</a>, the exception being the ACT studies (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>), which used <a href="./references#CD001860-bbs2-0102" title="DawsonCR , JonesBR , TarizzoML . A Guide to Trachoma Control. Geneva: World Health Organization, 1981. ">Dawson 1981a</a>. Almost all studies (except <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>) did some form of assessment of ocular infection using a variety of techniques, but most commonly polymerase chain reaction (PCR). Five studies assessed resistance (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). None of the studies assessed resistance of <i>C trachomatis</i> to antibiotics, but a number of other bacteria were considered (<i>Streptococcus pneumoniae</i> , <i>Staphylococcus aureas</i> , <i>Escherichia coli</i>), as well as genetic determinants of macrolide resistance. </p> <div class="table" id="CD001860-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cluster‐randomised studies: outcomes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active trachoma</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ocular infection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resistance</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using nucleic acid amplification test.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lytA+<br/> ermB–/mefA/E–<br/> ermB+/mefA/E–<br/> ermB–/mefA/E+<br/> ermB+/mefA/E+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>E coli</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae<br/> S aureus</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i><br/> mefA+/ermB2<br/> mefA+/ermB+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1986</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LCR: ligase chain reaction<br/> PCR: polymerase chain reaction </p> </div> </div> </section> </section> </section> <section id="CD001860-sec-0080"> <h4 class="title">Excluded studies</h4> <p>We excluded 63 studies for the following reasons (<a href="./references#CD001860-sec-0167" title="">Characteristics of excluded studies</a>). </p> <p> <ul id="CD001860-list-0021"> <li> <p>Types of studies: not RCTs (33 studies).</p> </li> <li> <p>Types of participants: not people with trachoma or not conducted in a trachoma endemic area (4 studies). </p> </li> <li> <p>Types of interventions: not a relevant intervention or comparator (21 studies).</p> </li> <li> <p>Types of outcomes: eye outcomes not measured, or assessed effect of antibiotics on trichiasis only (4 studies). </p> </li> <li> <p>Other reason: study not done (1 study), trial report not found (1 study).</p> </li> </ul> </p> </section> </section> <section id="CD001860-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001860-fig-0002">Figure 2</a> and <a href="#CD001860-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001860-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD001860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001860-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD001860-sec-0082"> <h4 class="title">Allocation</h4> <p>Twelve studies described adequate methods of generating an unpredictable sequence, using either computer‐generated sequences or random number tables. We considered that allocation concealment was not an issue for cluster‐randomised trials, and graded all 12 cluster‐randomised studies as at low risk of bias for this domain. Three of the individually randomised studies reported adequate methods of allocation concealment. The remaining studies reported insufficient detail to judge the risk of selection bias. </p> </section> <section id="CD001860-sec-0083"> <h4 class="title">Blinding</h4> <p>We considered performance and detection bias together, but separated the two main outcomes (active trachoma and ocular infection) because we considered that masking would have a different impact on these two outcomes. We considered that the issues of performance and detection bias for antimicrobial resistance were likely to be similar to those for ocular infection, as antimicrobial resistance is also assessed using laboratory tests.  </p> <section id="CD001860-sec-0084"> <h5 class="title">Individually randomised studies</h5> <section id="CD001860-sec-0085"> <h6 class="title">Active trachoma</h6> <p>In most of the individually randomised studies the treatments were quite different, either comparisons with no treatment, or comparing oral and topical treatments. Only four studies used placebo treatments to mask the study arms: three studies compared active treatment to placebo (<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>; <a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>), and one study compared oral and topical azithromycin with equivalent placebo treatments in each arm (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>). We graded these studies as at low risk of bias for performance and detection bias for active trachoma. A number of studies mentioned masking, particularly of outcome assessors. Masking was not well described in general, and we marked these studies as having an unclear risk of bias for performance and detection bias for active trachoma, given that the interventions were so clearly different. We graded studies where masking was not mentioned as at high risk of bias (<a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>). </p> </section> <section id="CD001860-sec-0086"> <h6 class="title">Ocular infection</h6> <p>Fewer studies measured ocular infection. Where masking was described, these were graded in general as having low risk of bias. Two of the individually randomised studies did not describe masking of laboratory samples and so were graded as at unclear risk of bias (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>). </p> </section> </section> <section id="CD001860-sec-0087"> <h5 class="title">Cluster‐randomised studies</h5> <section id="CD001860-sec-0088"> <h6 class="title">Active trachoma</h6> <p>All the comparisons in the cluster‐randomised studies were obviously different, and none of the studies reported using placebos. We therefore graded these studies as at high risk of bias, unless they reported efforts to mask the assessment of trachoma and/or attempted to minimise knowledge of the other arms of the study, in which case we graded them as at unclear risk of bias. </p> </section> <section id="CD001860-sec-0089"> <h6 class="title">Ocular infection (and antimicrobial resistance where assessed)</h6> <p>We graded the majority of studies that examined these outcomes as at low risk of bias, as efforts to mask the laboratory assessment were generally well described. Three studies described masking procedures in insufficient detail (<a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>; <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>). </p> </section> </section> </section> <section id="CD001860-sec-0090"> <h4 class="title">Incomplete outcome data</h4> <p>Only eight studies provided data suggesting that incomplete outcome data were unlikely to bias the results, that is they reported high follow‐up rates (greater than 80%) that were reasonably equal between intervention groups (<a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a>; <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>; <a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>). We graded seven studies with high or unequal loss to follow‐up as at high risk of attrition bias (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>; <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>; <a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a>; <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>). In another study, people were excluded because of inadequate treatment, and it was not clear to which group this applied (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>); this study was also graded as at high risk of attrition bias. Attrition bias was difficult to judge for the remaining studies, which we graded as at unclear risk of bias. </p> </section> <section id="CD001860-sec-0091"> <h4 class="title">Selective reporting</h4> <p>There was little suggestion of selective outcome reporting. <a href="#CD001860-tbl-0007">Table 3</a> and <a href="#CD001860-tbl-0010">Table 6</a> show the outcome‐reporting grid. In most cases where an outcome was not reported it was because the study follow‐up was not conducted at that time point, which is unlikely to introduce bias. <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> did not publish data on active trachoma, but this information was supplied by the authors. In two studies (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>; <a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>), it was clear that data on ocular infection had been collected but not reported. </p> </section> <section id="CD001860-sec-0092"> <h4 class="title">Other potential sources of bias</h4> <section id="CD001860-sec-0093"> <h5 class="title">Recruitment bias</h5> <p>Recruitment bias can occur when individuals are recruited to the trial after the clusters have been randomised, as the knowledge of whether each cluster is an ‘intervention’ or ‘control’ cluster could affect the types of participants recruited (<a href="./references#CD001860-bbs2-0113" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). None of the included studies discussed this issue.   </p> </section> <section id="CD001860-sec-0094"> <h5 class="title">Baseline imbalances</h5> <p>When small numbers of clusters are randomised, there is a possibility of chance baseline imbalance between the randomised groups in terms of either the clusters or the individuals (<a href="./references#CD001860-bbs2-0113" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This was a problem with some of the cluster‐randomised trials included in this review. Four of the trials randomised only two communities to treatment or control (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>; <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>). Reporting of the baseline comparability of clusters or statistical adjustment for baseline characteristics can help reduce concern about the effects of baseline imbalances (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>), however it is difficult to interpret differences in treatment effect between only two communities because there may be some other unknown confounding factor that explains the difference in effect. In <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>, eight communities were pair‐matched. The more recent cluster‐randomised studies were larger: <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> (24 communities); <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> (32 communities); <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> (48 communities); <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> (48 communities); <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> (16 communities); <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> (96 communities).   </p> </section> </section> </section> <section id="CD001860-sec-0095"> <h3 class="title" id="CD001860-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD001860-tbl-0001"><b>Summary of findings for the main comparison</b> Antibiotic versus control for trachoma: individuals</a>; <a href="./full#CD001860-tbl-0002"><b>Summary of findings 2</b> Oral versus topical antibiotic for trachoma: individuals</a>; <a href="./full#CD001860-tbl-0003"><b>Summary of findings 3</b> Oral azithromycin compared to control for trachoma: communities</a>; <a href="./full#CD001860-tbl-0004"><b>Summary of findings 4</b> Oral azithromycin compared to topical tetracycline for trachoma: communities</a> </p> <section id="CD001860-sec-0096"> <h4 class="title">Comparison 1: Any antibiotic versus control (individuals)</h4> <section id="CD001860-sec-0097"> <h5 class="title">Primary outcome: active trachoma</h5> <p><a href="./references#CD001860-fig-0004" title="">Analysis 1.1</a> shows the effect of any antibiotic treatment on active trachoma at three months. Nine trials randomising 1961 people contributed to this analysis. There was considerable heterogeneity between trials (I<sup>2</sup> = 73%). The treatment effects observed in the different trials ranged from a risk ratio of 0.40 (95% confidence interval (CI) 0.20 to 0.79), <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>, to a risk ratio of 1.02 (95% CI 0.83 to 1.25), <a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>. However, most of the trials suggested an apparent beneficial effect of treatment on active trachoma measured at three months follow‐up. The pooled risk ratio was 0.78 (95% CI 0.69 to 0.89). We judged this to be low‐certainty evidence, downgrading for risk of bias and inconsistency (<a href="./full#CD001860-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD001860-fig-0005" title="">Analysis 1.2</a> shows the effect of any antibiotic treatment on active trachoma at 12 months. Four trials randomising 1035 people contributed to this analysis. Again there was evidence of considerable heterogeneity between trials (I<sup>2</sup> = 90%). The treatment effects observed in the different trials ranged from a risk ratio of 0.50 (95% CI 0.41 to 0.62), <a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>, to a risk ratio of 1.05 (95% CI 0.88 to 1.24), <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>. However, three of the four trials showed a statistically significant beneficial effect of treatment on active trachoma measured at 12 months follow‐up. The pooled risk ratio was 0.74 (95% CI 0.55 to 1.00). We judged this to be low‐certainty evidence, downgrading for serious limitations in study design and inconsistency (<a href="./full#CD001860-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD001860-sec-0098"> <h6 class="title">Subgroup analysis: oral antibiotics versus control compared with topical antibiotics versus control </h6> <p><a href="./references#CD001860-fig-0006" title="">Analysis 1.3</a> shows the results separately for the trials that considered oral antibiotic versus control and the trials that considered topical antibiotic versus control on active trachoma at three months. Although statistical heterogeneity was reduced by considering these trials separately, substantial heterogeneity remained (I<sup>2</sup> of 60% and 68%). The pooled estimate of treatment effect for oral antibiotics on active trachoma at three months was 0.81 (95% CI 0.67 to 0.97) and for topical antibiotics 0.82 (95% CI 0.72 to 0.92). A similar picture was seen for active trachoma at 12 months (<a href="./references#CD001860-fig-0007" title="">Analysis 1.4</a>). Subgroup analyses such as these can be misleading because there may be other reasons for differences between trials apart from the type of antibiotic used. Direct comparison of oral versus topical antibiotic within trials is a more reliable estimate of relative effect. </p> </section> </section> <section id="CD001860-sec-0099"> <h5 class="title">Secondary outcome: <i>C trachomatis</i> infection </h5> <p><a href="./references#CD001860-fig-0008" title="">Analysis 1.5</a> shows the effect of any antibiotic treatment on ocular <i>C trachomatis</i> infection at three months. Fewer trials contributed to this analysis (4 trials, n = 297). However, in contrast to the effect on active trachoma, there was no evidence of heterogeneity in treatment effect between trials (I<sup>2</sup> = 0%). The treatment effect appeared to be of a similar order of effect as for active trachoma, but did not achieve conventional levels of statistical significance (pooled risk ratio of 0.81, 95% CI 0.63 to 1.04). We judged this to be low‐certainty evidence, downgrading for serious limitations in study design and imprecision (<a href="./full#CD001860-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD001860-fig-0009" title="">Analysis 1.6</a> shows the effect of any antibiotic treatment on <i>C trachomatis</i> infection at 12 months. Only one trial provided data on ocular chlamydial infection at 12 months (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>). The effect was strong, with a risk ratio of 0.25. Although this was statistically significant, the estimate of treatment effect was imprecise with a wide confidence interval (0.08 to 0.78), reflecting the small sample size of the trial. We judged this to be low‐certainty evidence, downgrading for very serious limitations in study design: one small study at risk of bias. </p> <p>One source of clinical heterogeneity in these trials was whether oral or topical antibiotic was used. One of the objectives of this review was to compare oral and topical treatment, in particular oral azithromycin and topical tetracycline. </p> <section id="CD001860-sec-0100"> <h6 class="title">Subgroup analysis: oral antibiotics versus control compared with topical antibiotics versus control </h6> <p>Data were insufficient to make a reliable comparison of the effects of oral and topical antibiotics versus control on <i>C trachomatis</i> infection (<a href="./references#CD001860-fig-0010" title="">Analysis 1.7</a>; <a href="./references#CD001860-fig-0011" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD001860-sec-0101"> <h5 class="title">Secondary outcome: antimicrobial resistance</h5> <p>None of the studies assessed antimicrobial resistance.</p> </section> <section id="CD001860-sec-0102"> <h5 class="title">Adverse effects</h5> <p><a href="#CD001860-tbl-0011">Table 7</a> summarises the information on adverse effects reported in the individually randomised studies. In 5 of the 14 individually randomised studies, there was no mention of adverse effects in the study report. </p> <div class="table" id="CD001860-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects: individually randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic (number of people treated)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Report</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline (77)</p> <p>Tetracycline derivative GS2989 (75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (97)</p> <p>Topical tetracycline with oral erythromycin in severe cases (97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Table 2 on page 454 reports adverse effects. Abdominal pain reported more often in azithromycin group (26% versus 16%, P = 0.09). Other effects: diarrhoea, vomiting, fever, headache, body pain, other similar between study groups. </p> <p>"There were no serious adverse reactions and both treatments were well tolerated. All symptoms resolved spontaneously and none required treatment." 1 study participant died, probably due to malaria. He had received topical tetracycline. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (160)</p> <p>Tetracycline (154)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin topical 2‐day regimen (222) 3‐day (220) and oral azithromycin (214)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ocular adverse events were reported in 10.8%, 8.9% and 13.1% of patients in the 2‐day, 3‐day and oral treatment groups respectively. Systemic adverse events were reported in 2.6%, 10.2% and 9.0% of patients. None of the adverse events were treatment‐related events. One patient (3‐day group) had a serious unrelated adverse events (death due to head injury)." (page 670) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxycycline (44)</p> <p>Oxytetracycline (38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 &amp; 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> </p> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trisulfapyrimidines (33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No untoward reactions to sulfonamides were noted" (page 587)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline/polymyxin (43)</p> <p>Azithromycin (125)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In this trial, azithromycin was well tolerated and only two children (of 125 treated) complained of nausea" (page 367) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxypyridazine (112)</p> <p>Tetracycline (106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"3/155 students who received sulfamethoxypyridazine had adverse reactions to the drug. One girl developed a severe purpura associated with marked thrombocytopenia. She recovered following withdrawal of the drug and administration of corticosteroids. Two cases of diagnosed drug rash necessitated discontinuance of the drug. The nephrotic syndrome developed in one boy three months after completion of sulphonamide therapy, but the relationship of this development to therapy was not determined. No reactions or rashes occurred in the other two treatment groups" (page 453) (note: Table 3/Table 4 report 112 children treated with sulfamethoxypyridazine) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxycycline (49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Anorexia, nausea, vomiting or diarrhea occurred in three children between the 15th and 25th days of medication. Two of these children were receiving doxycycline, and the disturbances lasted only a single day in each child, in spite of continuing medication. Between day 21 and 28 of medication, transient macular rashes and one‐day illness with low‐grade fever and anorexia occurred in four children. Two of them had received drug, and two placebo. It is likely that an intercurrent, unrelated illness was responsible. Gross enamel dysplasia or tooth discoloration was not observed on examination 20 weeks after the end of medication." (page 222) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline (932)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfafurazole (140)</p> <p>Sulfadimethoxine (161)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (31)</p> <p>Tetracycline (29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects were noted" (page 844); and "The safety of a single oral dose of azithromycin has been demonstrated in this study. Similar to other clinical studies, no adverse effects developed in any of the patients in the azithromycin group" (page 845) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline (726)</p> <p>Sulfonamide (526)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No more than trivial reactions were observed in any of these three studies, to vaccine, to oil adjuvant, to eye ointment or to sulfa drug." (page 1581) </p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD001860-list-0022"> <li> <p>In <a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> abdominal pain was reported more often in the azithromycin group (26% versus 16%, P = 0.09). Other effects: diarrhoea, vomiting, fever, headache, body pain, other similar between two study groups. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> reported no treatment‐related adverse events. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> and <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> noted "No untoward reactions to sulfonamides". </p> </li> <li> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> reported that azithromycin was well tolerated, and that only two children (of 125 treated) complained of nausea. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> noted three adverse reactions to sulphamethoxypyridazine in 155 children given the drug. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> reported "Anorexia, nausea, vomiting or diarrhoea..." in two children out of 49 receiving doxycycline. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> reported no adverse effects in 31 people given azithromycin and 29 given tetracycline. </p> </li> <li> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> noted only trivial reactions. </p> </li> </ul> </p> </section> </section> <section id="CD001860-sec-0103"> <h4 class="title">Comparison 2: Oral versus topical antibiotics (individuals)</h4> <section id="CD001860-sec-0104"> <h5 class="title">Primary outcome: active trachoma</h5> <p><a href="./references#CD001860-fig-0012" title="">Analysis 2.1</a> shows the effect of oral versus topical antibiotic on active trachoma at three months from within‐trial comparisons (6 trials, n = 953). There was considerable statistical heterogeneity (I<sup>2</sup> = 63%). The estimates of effect were spread across the null line, with three trials reporting a beneficial effect of oral antibiotics, and three trials reporting a beneficial effect of topical antibiotics. Three of the six trials had findings consistent with no difference in effect (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>). We judged this to be moderate‐certainty evidence, downgrading one level for serious limitations in study design and one level for inconsistency as the study estimates ranged from 0.65 to 1.37 (<a href="./full#CD001860-tbl-0002">summary of findings Table 2</a>). </p> <p><a href="./references#CD001860-fig-0013" title="">Analysis 2.2</a> shows the effect of oral versus topical antibiotic on active trachoma at 12 months from within‐trial comparisons (5 trials, n = 886). There was considerable statistical heterogeneity (I<sup>2</sup> = 56%). The estimates of effect were spread across the null line, with three trials reporting a beneficial effect of oral antibiotics, and two trials reporting a beneficial effect of topical antibiotics. Three of the six trials had findings consistent with no difference in effect (<a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>; <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>; <a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a>). We judged this to be low‐certainty evidence, downgrading one level for serious limitations in study design and one level for inconsistency as the study estimates ranged from 0.66 to 1.15 (<a href="./full#CD001860-tbl-0002">summary of findings Table 2</a>). </p> <p>Examining the trials for clinical heterogeneity suggested that the interventions used in <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> were different. In particular, this study focused on "practical operational conditions", which meant that the topical treatments were unsupervised. A post hoc analysis excluding this trial from the analyses substantially reduced the observed inconsistency (I<sup>2</sup> = 0%) at three months, with a pooled risk ratio for the remaining five included trials of 1.04 (95% CI 0.94 to 1.16). Similar improvements in consistency were seen when <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> was excluded from the 12 months' analyses (I<sup>2</sup> changed from 56% to 29%, pooled risk ratio 1.01 (95% CI 0.85 to 1.20)). In the other trials, application of topical antibiotics was done by members of the research team or schoolteachers.  </p> </section> <section id="CD001860-sec-0105"> <h5 class="title">Secondary outcome: <i>C trachomatis</i> infection </h5> <p>Similarly for active trachoma at 12 months, there was no consistent evidence to support either oral or topical antibiotics being more effective for <i>C trachomatis</i> infection at three (<a href="./references#CD001860-fig-0014" title="">Analysis 2.3</a>) or 12 months (<a href="./references#CD001860-fig-0015" title="">Analysis 2.4</a>) (<a href="./full#CD001860-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD001860-sec-0106"> <h5 class="title">Secondary outcome: antimicrobial resistance</h5> <p>None of the studies assessed antimicrobial resistance.</p> </section> <section id="CD001860-sec-0107"> <h5 class="title">Adverse effects</h5> <p>See Comparison 1 above.</p> </section> </section> <section id="CD001860-sec-0108"> <h4 class="title">Comparison 3: Oral azithromycin versus topical tetracycline (individuals)</h4> <section id="CD001860-sec-0109"> <h5 class="title">Primary outcome: active trachoma</h5> <p><a href="./references#CD001860-fig-0016" title="">Analysis 3.1</a> and <a href="./references#CD001860-fig-0017" title="">Analysis 3.2</a> show the specific comparison between oral azithromycin and topical tetracycline for active trachoma at three and 12 months. There was considerable heterogeneity in the results of these studies for active trachoma (<a href="./references#CD001860-fig-0016" title="">Analysis 3.1</a>). As before, excluding <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> from the analyses substantially reduced the inconsistency (I<sup>2</sup> = 0%), and the pooled risk ratio of the two remaining trials was 1.01 (95% CI 0.80 to 1.28). Only two trials reported data at 12 months. <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> reported a beneficial effect of azithromycin compared to tetracycline (risk ratio 0.66, 95% CI 0.45 to 0.98). <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> reported a smaller effect that was not statistically significant (risk ratio 0.90, 95% CI 0.65 to 1.23). </p> <p>We have not included data from <a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> in the graphical analyses because they compared oral antibiotic (single dose azithromycin) with a combination of topical/oral antibiotic (topical tetracycline with oral erythromycin for severe cases). A total of 194 people with active trachoma were randomly allocated to treatment, 97 in each group. Approximately 60% of these people were antigen positive at baseline. At 26 weeks, 21/97 had active trachoma in the azithromycin group and 27/97 in the tetracycline/erythromycin group (risk ratio 0.78, 95% CI 0.47 to 1.28). Approximately 42% of each group were antigen positive. We have also not included data from <a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> in the meta‐analyses because they compared oral azithromycin with two regimens of topical azithromycin, and treated people accompanying the children to the treatment centre. They found that trachoma resolved in 93.0%, 96.3%, and 96.6% of the two‐day group, three‐day group, and oral treatment group 60 days after treatment. </p> </section> <section id="CD001860-sec-0110"> <h5 class="title">Secondary outcome: <i>C trachomatis</i> infection </h5> <p><a href="./references#CD001860-fig-0018" title="">Analysis 3.3</a> and <a href="./references#CD001860-fig-0019" title="">Analysis 3.4</a> show the specific comparison between oral azithromycin and topical tetracycline for <i>C trachomatis</i> infection at three and 12 months. Two studies reported this outcome at three months. The results of these studies differed: <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> risk ratio 0.57, 95% CI 0.14 to 2.30, favouring azithromycin, and <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> risk ratio 1.30, 95% CI 0.41 to 4.11, favouring tetracycline. At 12 months there were only data from <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a>, but with few events the effect estimate was imprecisely estimated (risk ratio 0.50, 95% 0.18 to 1.43). </p> </section> <section id="CD001860-sec-0111"> <h5 class="title">Secondary outcome: antimicrobial resistance</h5> <p>None of the studies assessed antimicrobial resistance.</p> </section> <section id="CD001860-sec-0112"> <h5 class="title">Adverse effects</h5> <p>See Comparison 1 above.</p> </section> </section> <section id="CD001860-sec-0113"> <h4 class="title">Comparison 4: Oral antibiotics versus control (communities)</h4> <p>Four cluster‐randomised community‐based trials compared antibiotic to no or delayed treatment: three studies of oral azithromycin (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>) and one study of topical tetracycline (<a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>). </p> <section id="CD001860-sec-0114"> <h5 class="title">Primary outcome: active trachoma</h5> <p>None of the studies followed up at three months. </p> <p>Two studies published on active trachoma at 12 months (<a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>) and one study provided unpublished data (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>).  </p> <p>In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>, 258/634 sentinel children aged 0 to 9 years in 12 communities treated with a single dose of azithromycin had active trachoma at 12 months compared with 429/613 children in communities where treatment was delayed to 12 months (risk ratio 0.58, 95% CI 0.52 to 0.65). The results of this study were reasonably robust to assumptions about the intracluster correlation coefficient (ICC): adjusting for an ICC of 0.2 gave a 95% CI of 0.41 to 0.83. </p> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> reported data as median community prevalence. At 12 months, the median community prevalence of active trachoma was 9.3% in communities given one single dose of azithromycin (range 0 to 38.9%) and 8.2% in communities that had not been treated (range 0 to 52.9%). </p> <p>There are several potential reasons for the difference between <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> and <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>: (1) The prevalence of active trachoma in the population of <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> was low (median 6%). In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> disease prevalence was much higher: over 70% of children had active trachoma at baseline in the intervention groups; (2) We judged <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> largely at low risk of bias but <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> was a mixture of unclear and high risk of bias. In particular, the authors reported that reported that people taking part in the 12‐month follow‐up were less likely to report exposure to a face‐washing educational campaign and were less likely to live within 30 minutes of a water source; (3) the coverage of mass drug administration was lower in <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> at 73% whereas in <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> it was over 80%.  </p> <p>In <a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> four villages were randomly allocated in factorial fashion to treatment with 1% oxytetracycline or health education. Individuals treated with tetracycline experienced a higher cure rate than people who were not, and communities treated with tetracycline experienced a lower incidence and prevalence of the disease. </p> </section> <section id="CD001860-sec-0115"> <h5 class="title">Secondary outcome: <i>C trachomatis</i> infection </h5> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> and <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> reported <i>C trachomatis</i> infection at 12 months (<a href="./references#CD001860-fig-0021" title="">Analysis 4.2</a>). In both studies communities treated with azithromycin were less likely to have <i>C trachomatis</i> infection at 12 months compared to untreated communities. These studies gave different estimates of effect (0.61 in <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> and 0.32 in <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>, I<sup>2</sup> = 97%). The pooled risk ratio was 0.35 (95% CI 0.21 to 0.60). Although it is likely that the size of the pooled effect estimate is unreliable, given the differences between the studies, both of the studies indicated a statistically significant beneficial effect of antibiotic treatment on <i>C trachomatis</i> infection. Again, we judged this to be moderate‐certainty evidence, downgrading for inconsistency (<a href="./full#CD001860-tbl-0003">summary of findings Table 3</a>). </p> <p>The conclusions did not change as a result of adjusting for the extra variation introduced by the cluster design of the studies. Adjusting for an ICC of 0.2 gave a confidence interval for the pooled risk ratio of 0.20 to 0.63. </p> <p>In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> communities were treated at 12 months. However, at a later stage after four years of mass treatment, communities were randomised to continuation versus discontinuation of annual or biannual mass treatment. In the discontinuation arm, the mean prevalence of infection in children aged 0 to 9 years increased from 8.3% (95% CI 4.2% to 12.4%) at baseline (0 months) to 14.7% (95% CI 8.7% to 20.8%, P = 0.04) at 36 months. The prevalence of <i>C trachomatis</i> in communities randomised to continuation of mass treatment was 7.2% (95% CI 3.3% to 11.0%) at baseline and 6.6% (95% CI 1.1% to 12.0%, P = 0.64) at 36 months. </p> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> reported data as median community prevalence. At 12 months, the median community prevalence of ocular infection was 0% in communities given one single dose of azithromycin (range 0 to 14.3%) and 0% in communities that had not been treated (range 0 to 14.3%). </p> </section> <section id="CD001860-sec-0116"> <h5 class="title">Secondary outcome: antimicrobial resistance</h5> <p>Five studies, all taking place in Africa, assessed antimicrobial resistance  (<a href="#CD001860-tbl-0012">Table 8</a>) (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). Three of these studies compared azithromycin with no azithromycin (<a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). In <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> azithromycin was given once a year for three years; in <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> azithromycin was given every three months for one year; and in <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> azithromycin was given twice a year for three years. Two studies compared different frequencies of azithromycin administration. <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> compared azithromycin twice a year for two years to azithromycin once a year for two years. <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared azithromycin once a year for three years to azithromycin once a year for one year. In all five studies antibiotic resistance was assessed in children, although the age ranges differed.  </p> <div class="table" id="CD001860-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Studies reporting antibiotic resistance: characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteria or genetic determinant</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carriage body reservoir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample type</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. "><b>PRET Niger</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger (Matameye district in the Zinder region)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ twice a year for 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 2 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lytA+<br/> ermB–/mefA/E–<br/> ermB+/mefA/E–<br/> ermB–/mefA/E+<br/> ermB+/mefA/E+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and 24 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania (Kongwa district)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>E coli</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rectal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Erythromycin </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 1, 3, and 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 15 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae<br/> S aureus</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Clindamycin </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group: 1 month before and 1 month and 6 months after 3rd annual round of MDA<br/> Comparator group: 30 months after 1 annual round of MDA </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia (Goncho Siso Enese woreda district, Amhara zone)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ every 3 months for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ (control communities treated at 12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i><br/> mefA+/ermB2<br/> mefA+/ermB+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Clindamycin<br/> Penicillin<br/> Tetracycline </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia (Goro district of the Gurage zone of southern Ethiopia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ twice a year for 3 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Tetracycline<br/> Penicillin<br/> TMP‐SMX </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 36, 42, and 54 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AZ: azithromycin<br/> MDA: mass drug administration<br/> TMP‐SMX: trimethoprim‐sulfamethoxazole  </p> <p>*All the studies were cluster‐randomised trials, and AZ was delivered to the whole community (mass drug administration). </p> </div> </div> <p>None of the studies assessed antibiotic resistance in<i>C trachomatis</i> . Three studies assessed <i>S pneumoniae</i> (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>); one study assessed <i>S aureus</i> (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>); and one study assessed <i>E coli</i> (<a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>). Carriage was nasopharyngeal, with the exception of <i>E coli</i>, which was gastrointestinal.  Four studies assessed resistance to azithromycin. <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> and <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> assessed genetic evidence of resistance to macrolides and azithromycin, respectively. Other antibiotics were also considered: erythromycin (<a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>), clindamycin (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>), tetracycline (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>), penicillin (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>), and trimethoprim‐sulfamethoxazole (TMP‐SMX) (<a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>).  </p> <p>Maximum follow‐up (after baseline mass drug administration (MDA) treatment) was six months (<a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>), 12 months (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>), 24 months (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>), 30 months (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>), and 54 months (<a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). </p> <p>Due to the heterogeneity of studies, outcomes, and reporting, we did not perform any meta‐analysis of antimicrobial resistance outcomes. </p> <section id="CD001860-sec-0117"> <h6 class="title">Antibiotic resistance in <i>S pneumoniae</i> </h6> <p><a href="#CD001860-tbl-0013">Table 9</a> show the results of the studies investigating resistance to <i>S pneumoniae</i> (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>).  </p> <div class="table" id="CD001860-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Antibiotic resistance to Streptococcus pneumoniae </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention***</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence intervals</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b>‐‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 to 33.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 to 9.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 to 9.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 to 244</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 to 2922</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CLINDAMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 to 11.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 to 12.1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>PENICILLIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 to 8.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 to 9.52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 to 72.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>TETRACYCLINE</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 to 2.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 to 2.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 to 6.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>TRIMETHOPRIM‐SULFAMETHOXAZOLE</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 to 2.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 2.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin<br/> MDA: mass drug administration </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared AZ once a year for 3 years with AZ once a year for 1 year; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> compared AZ every 3 months for 12 months with no AZ; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> compared AZ twice a year for 3 years with no AZ.<br/> **Follow‐up is months after baseline (i.e. first MDA) unless otherwise indicated.<br/> ***<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> and <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> reported average percentages across communities, and these are the percentages reported in this table. We estimated n/N using these percentages and additional information in the text of the paper. Figures for n/N were used to calculate the risk ratio and 95% confidence interval in RevMan 5. There may be minor discrepancies due to rounding between the raw numbers, percentages and risk ratios. The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with pneumococcal carriage only.</p> </div> </div> <p>In <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> azithromycin/macrolide resistance was assessed one month before, one month after, and six months after the third annual round of MDA in two communities. This was compared to antibiotic resistance 30 months after one round of MDA in six communities. There were few cases of resistance to azithromycin: no cases one month before the third round of azithromycin MDA; 5/417 (1.2%) one month after; and 3/343 (0.9%) six months after. In the comparator group there was one case of resistance in 400 children (0.3%) 30 months after one annual round of MDA. The risk ratio comparing intervention (six months after the third round of mass treatment) and control (30 months after one annual round of mass treatment) suggested an increased risk of resistance in the intervention communities (risk ratio 3.5, 95% CI 0.4 to 33.5). However, wide confidence intervals, due to the sparse data, were compatible with increased or decreased risk. </p> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> compared antibiotic resistance in 12 communities allocated to mass treatment with azithromycin every three months for 12 months, which was compared to antibiotic resistance in 12 communities that did not receive azithromycin for 12 months. At baseline in the intervention communities, on average 3.6% of children were carrying <i>S pneumoniae</i> resistant to azithromycin.  At 12 months this had increased to 46.9%. The 12 untreated control communities were not assessed at baseline, but at 12 months had an average azithromycin‐resistant <i>S pneumoniae</i> carriage risk of 9.2% (risk ratio 5.1, 95% CI 2.8 to 9.3). These analyses are based on the proportion of swabbed children who were classified as resistant. Similar findings were seen for analyses of the proportion of pneumococcal isolates that were classified as resistant (risk ratio 5.6, 95% CI 3.1 to 9.9). The confidence intervals around the effect estimate do not take into account the cluster design of the study. In the study report, confidence intervals were only provided for risk estimates by group and not for the risk ratio. Comparing these with confidence intervals calculated ignoring the cluster design suggested that any design effect in this study would be less than 1.5. Repeating the risk ratio calculations assuming a conservative design effect of 2 suggests the lower confidence interval would be not less than 2.  </p> <p>Similar results were seen in <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>. A substantial proportion of children in eight communities treated with azithromycin twice a year for three years were carrying <i>S pneumoniae</i> resistant to azithromycin at follow‐up visits: 28.2% at 24 months and 76.8% at 36 months. This proportion decreased after cessation of azithromycin and was 30.6% at 42 months and 20.8% at 54 months. Data from eight untreated control communities had a lower risk of resistance: 0.9% at 24 months and 0% at 36 months. Risk ratio was 34.0 (95% CI 4.7 to 244) at 24 months and 183.4 (95% CI 11.5 to 2922) at 36 months. Again, repeating analyses assuming a design effect of 2, the lower confidence intervals were always well above 1.  </p> <p>In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> an increased risk of clindamycin resistance was seen in the intervention communities (risk ratio 4, 95% CI 1.4 to 11.7), but the prevalence of resistance was lower than in other studies: 13.3% in communities treated every three months compared to 3.3% in untreated communities. Similar results were seen for analyses of isolates of <i>S pneumoniae</i> infection. </p> <p>Both <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> and <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> investigated penicillin resistance in <i>S pneumoniae</i>. There were very few cases (0 or 1 only) in both studies. </p> <p>Both <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> and <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> investigated tetracycline resistance in <i>S pneumoniae</i>. In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> 10% of children had tetracycline‐resistant <i>S pneumoniae</i> at baseline; this increased to 28.4% in communities given mass treatment with azithromycin every three months. This was compared to 17.5% resistance in the non‐treated communities at 12 months (risk ratio 1.6, 95% CI 1.01 to 2.6). An analysis with design effect of 2 reduced the lower confidence interval to below 1. Similar results were seen when the analyses were restricted to isolates of <i>S pneumoniae</i> infection. In <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> tetracycline resistance was seen in 36.5%, 68.7%, 57.2%, and 38.7% of samples at 24, 36, 42, and 54 months, respectively. This was compared to 18.9% and 15.7% resistance in the control group at 24 months and 36 months (risk ratio 1.9 (95% CI 1.2 to 3.0) and 4.3 (2.8 to 6.6), respectively). The lower confidence interval for the latter analysis remained above 1 with a design effect of 2.  </p> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> was the only study to look at TMP‐SMX and found a similar order of magnitude of resistance in intervention (approximately 8%) and comparator groups (approximately 7% at 36 months) (risk ratio 1.1, 95% CI 0.5 to 2.8). </p> </section> <section id="CD001860-sec-0118"> <h6 class="title">Antibiotic resistance in <i>S aureus</i> </h6> <p><a href="#CD001860-tbl-0014">Table 10</a> shows the results of the studies investigating resistance to <i>S aureus</i> (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>). </p> <div class="table" id="CD001860-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Antibiotic resistance to Staphylococcus aureus </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence interval***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/414</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after annual round of MDA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 to 11.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142/161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 to 7.1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CLINDAMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/414</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 to 24.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128/161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 to 16.5</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin<br/> MDA: mass drug administration </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared AZ once a year for three years with AZ once a year for one year.<br/> **Follow‐up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.<br/> ***The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with <i>S.aureus</i> carriage only.  </p> </div> </div> <p>Only one study reported resistance to <i>S aureus</i> (<a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>). This study compared azithromycin once a year for three years with azithromycin once a year for one year. </p> <p>Resistance to azithromycin rose from 8.9% one month before the third round of mass treatment to 34.1% one month after and dropped again to 7.3% six months later in two communities. This was higher than the prevalence of resistance in six comparator communities (1.6%) that had received 1 dose of azithromycin 30 months previously (risk ratio 4.6, 95% CI 1.9 to 11.0). A similar change over time was seen with clindamycin (5.8% one month before third round; 30.7% one month after third round; and 5.8% six months after third round), with a low risk in comparator communities (0.8% prevalence 30 months after baseline) risk ratio 7.3 (95% CI 2.2 to 24.3). </p> </section> <section id="CD001860-sec-0119"> <h6 class="title">Antibiotic resistance in <i>E coli</i> </h6> <p>One study reported resistance to <i>E coli</i> (<a href="#CD001860-tbl-0015">Table 11</a>) (<a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>). In the four intervention communities, azithromycin resistance increased from 16.3% at baseline to 61.2% one month after mass treatment, thereafter decreasing to 42.1% at three months, and 31.3% at six months. In the four untreated communities, azithromycin resistance was lower: 20.8%, 18.7%, 15.9%, and 20.0% (risk ratio at six months 1.6, 95% CI 0.8 to 3.0). A similar pattern was seen for erythromycin. In the four intervention communities, erythromycin resistance varied from 26.0% at baseline to 76.0% at one month after mass treatment, to 54.9% at three months, and 38.6% at six months. In the four untreated communities, erythromycin resistance was lower: 22.9%, 28.4%, 23.8%, and 26.0% (risk ratio at six months 1.8, 95% CI 0.8 to 3.9). </p> <div class="table" id="CD001860-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antibiotic resistance to Escherichia coli </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence intervals***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 1.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/129</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 4.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 to 4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/324</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 to 4.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 to 3.4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ERYTHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 to 2.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98/129</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 to 13.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 6.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 to 1.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8 to 9.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/324</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 to 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 to 4.1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> compared AZ once a year for three years with no AZ.<br/> **Follow‐up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.<br/> ***The 95% confidence intervals for the risk ratio are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with <i>E.coli</i> carriage only. </p> </div> </div> </section> </section> <section id="CD001860-sec-0120"> <h5 class="title">Adverse effects</h5> <p><a href="#CD001860-tbl-0016">Table 12</a> summarises the information on adverse effects reported in the cluster‐randomised studies. In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> data on adverse effects due to azithromycin were collected systematically: </p> <div class="table" id="CD001860-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse effects: cluster‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic (number of communities and people treated)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Report</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 2 &amp; 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (6 communities, approximately 3800)</p> <p>Tetracycline (6 communities, approximately 2400)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 4 communities included in the study. </p> <p>Azithromycin (214)</p> <p>Tetracycline (161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (1139)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported no adverse events on clinical trials register (clinicaltrials.gov/ct2/show/results/NCT00618449)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, approximately 6000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report, but "a data and safety monitoring committee met annually to review results and serious adverse events" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (32 communities, approximately 12,000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no serious adverse events reported in either arm."</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, 29,091)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline (346)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (over 16,000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"We recorded no reported serious adverse events attributed to study medication. 96 deaths were recorded in subkebeles in the children‐treated group and 126 deaths recorded in those in the control group. At 12 months a survey was undertaken to assess adverse effects in the treated population (n=671, 96 side‐effects reported). [.. ] 56 (11.3%) patients reported abdominal pain, vomiting, and nausea, whereas diarrhoea, constipation and related issues accounted for 16 (2.4%) of complaints. Four (0.6%) patients reported haemorrhoid or other as side effects" (House and colleagues, page 1115). "In a trachoma‐endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children" (Porco and colleagues, conclusion of abstract) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (16 communities, 4790)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no serious adverse events due to the study medicine reported"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, unclear how many people)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events were associated with MDA."</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MDA: mass drug administration</p> </div> </div> <p> <ul id="CD001860-list-0023"> <li> <p>96/671 individuals treated with azithromycin reported an adverse effect of treatment (14.3%, 95% CI 11.7% to 17.2%); 72 of these 96 people (75%) had gastrointestinal effects (abdominal pain, vomiting, nausea, diarrhoea, constipation, and related issues) (10.7% of total sample of 671 people, 95% CI 8.5% to 13.3%); </p> </li> <li> <p>no serious adverse events were recorded in this study;</p> </li> <li> <p>a specific analysis of childhood mortality suggested that azithromycin treatment reduced the rate of childhood mortality in these communities. The mortality rate for children aged 1 to 9 years was 4.1 per 1000 person‐years (95% CI 3.0 to 5.7) in the treated communities compared to 8.3 per 1000 person‐years (95% CI 5.3 to 13.1) in the untreated communities. </p> </li> </ul> <ul id="CD001860-list-0024"> <li> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>, <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>, <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>, <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>, and <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> reported that there were no serious adverse events. </p> </li> </ul> </p> <p>Notably, two other large cluster‐randomised studies of azithromycin did not comment on adverse events (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>), but in <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> "a data and safety monitoring committee met annually to review results and serious adverse events". </p> </section> </section> <section id="CD001860-sec-0121"> <h4 class="title">Comparison 5: Oral azithromycin versus topical tetracycline (communities)</h4> <section id="CD001860-sec-0122"> <h5 class="title">Primary outcome: active trachoma</h5> <p>Only one study compared oral and topical community‐based treatment for trachoma, the Azithromycin in Control of Trachoma study (ACT). As this study took place in three different countries in Africa (Egypt, The Gambia, and Tanzania), it is included in the analyses as three separate studies. </p> <p>Even though all three studies had the same interventions and the one study protocol, there was still considerable heterogeneity of effect. However, it should be noted that in two locations only two communities were randomised to oral versus topical treatment (<a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>). </p> <p>The effect of community‐based treatment with azithromycin versus topical tetracycline on active trachoma is shown in <a href="./references#CD001860-fig-0022" title="">Analysis 5.1</a> and <a href="./references#CD001860-fig-0023" title="">Analysis 5.2</a>. In <a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> and <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>, there was some evidence that azithromycin was more effective than topical tetracycline in reducing the risk of active trachoma at three and 12 months. However, these results were not very robust to assumptions about the ICC. Adjusting for an ICC of 0.05 resulted in confidence intervals including 1 for all the results. In <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>, the findings were less consistent, with a risk ratio greater than 1 (favouring topical treatment) for active trachoma at three and 12 months. We judged this to be low‐certainty evidence, downgrading for serious limitations in study design and inconsistency (<a href="./full#CD001860-tbl-0004">summary of findings Table 4</a>). </p> <p>One further study with a more complex design compared targeted azithromycin combined with surgery versus surgery alone. People with active trachoma in the control group received tetracycline, as did non‐index cases in the intervention group (<a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>). The proportion of people with active trachoma at 12 months was 21/523 in the intervention group compared with 35/994 in the control (risk ratio 1.14, 95% CI 0.67 to 1.94). The figures for ocular infection were: 23/659 vs 68/1192 (risk ratio 0.61, 95% CI 0.39 to 0.97). </p> </section> <section id="CD001860-sec-0123"> <h5 class="title">Secondary outcome: <i>C trachomatis</i> infection </h5> <p>The effect of community‐based treatment with azithromycin versus topical tetracycline on active trachoma is shown in <a href="./references#CD001860-fig-0024" title="">Analysis 5.3</a> and <a href="./references#CD001860-fig-0025" title="">Analysis 5.4</a>. At three months, azithromycin appeared to be more effective than topical tetracycline in reducing the risk of <i>C trachomatis</i> infection. However, these results were not very robust to assumptions about the ICC. Adjusting for an ICC of 0.05 resulted in confidence intervals including 1 for all the results. In <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>, the findings were less consistent, with a risk ratio greater than 1 (favouring topical treatment) for <i>C trachomatis</i> infection at 12 months. We judged this to be low‐certainty evidence, downgrading for serious limitations in study design and inconsistency (<a href="./full#CD001860-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD001860-sec-0124"> <h5 class="title">Secondary outcome: antimicrobial resistance</h5> <p>See Comparison 4 above.</p> </section> <section id="CD001860-sec-0125"> <h5 class="title">Adverse effects</h5> <p>See Comparison 4 above.</p> </section> </section> <section id="CD001860-sec-0126"> <h4 class="title">Comparison 6: Annual versus different treatment frequencies</h4> <p>The included studies considered several different dosing strategies. These fall into three broad categories: applying mass treatment at different dosing intervals; applying cessation or stopping rules to mass treatment; and strategies to increase mass treatment coverage. </p> <section id="CD001860-sec-0127"> <h5 class="title">Mass administration of azithromycin at different dosing intervals</h5> <p>The WHO recommends annual treatment with antibiotics for communities where the prevalence of active trachoma in children aged 1 to 9 years is 10% or more (<a href="./references#CD001860-bbs2-0125" title="SolomonAW , ZondervanM , KuperH , BuchanJC , MabeyDC , FosterA . Trachoma Control: a Guide for Programme Managers. Geneva: World Health Organization, 2006. ">Solomon 2006</a>; <a href="./references#CD001860-bbs2-0135" title="World Health Organization. World Health Organization Strategic and Technical Advisory Group on Neglected Tropical Diseases. Monitoring and Evaluation Working Group Sub‐Group 2. Technical Consultation on Trachoma Surveillance; 2014 September 11−12, 2014 Task Force for Global Health; Decatur (GA). 2014. ">WHO 2014</a>). Four studies compared different dosing intervals with azithromycin versus annual treatment with azithromycin. The different dosing intervals evaluated were as follows. </p> <p> <ul id="CD001860-list-0025"> <li> <p>Two doses of azithromycin (day 0 and day 30) compared with one dose (day 0) for one year (<a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a>). </p> </li> <li> <p>Azithromycin (single dose) every three months for one year (children aged 1 to 10 years only) (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>). </p> </li> <li> <p>Azithromycin (single dose) every six months for two years (<a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). </p> </li> <li> <p>Azithromycin (single dose) every six months for three years (children aged 0 to 12 years only) (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>). </p> </li> <li> <p>Azithromycin (single dose) every six months for three years (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>). </p> </li> </ul> </p> <section id="CD001860-sec-0128"> <h6 class="title">Two doses of azithromycin (day 0 and day 30) compared with one dose (day 0) for one year </h6> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> compared two doses of azithromycin (day 0 and day 30) with a single dose of azithromycin (day 0) in 10 communities within the Maradi region of Niger with a high prevalence of clinical active trachoma in children aged 10 years and younger. This study is unpublished, but study results were available on the trials register (clinicaltrials.gov/ct2/show/results/NCT00618449). The results of this study were inconclusive. At one year, 19/679 (2.8%) participants in the two dose arm had <i>C trachomatis</i> infection compared with 12/668 (1.8%) in the single dose arm (risk ratio 1.56, 95% CI 0.76 to 3.18). The investigators reported that "Prevalence of infection in communities was less than predicted, as was return of infection post‐treatment, thus hypothesis could not be evaluated". </p> </section> <section id="CD001860-sec-0129"> <h6 class="title">Azithromycin (single dose) every three months for 12 months</h6> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> evaluated the treatment of children aged 1 to 10 years every three months for one year in 12 communities in Ethiopia. Active trachoma was reported for the children‐treated arm only. <a href="#CD001860-tbl-0017">Table 13</a> shows results for <i>C trachomatis</i> infection. At 12 months there was a lower prevalence of infection in children age 1 to 10 years in the communities where children were treated every three months (3.6%) compared with the communities where everyone was offered 1 annual dose (14.6%). Similar prevalence of infection at 12 months was observed in the two groups in people age 11 years and above (8.2% versus 6.2%). </p> <div class="table" id="CD001860-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Azithromycin (single‐dose) every 3 months for 12 months: mean community prevalence of infection with C trachomatis at 12 months</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention: children aged 1 to 10 years offered single‐dose oral  azithromycin every 3 months (n = 12 communities) </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator: everyone aged 1 year and older offered single‐dose oral azithromycin at first visit (baseline) (n = 12 communities) </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence % </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence %</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 6.4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 to 22.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults aged 11 years and older</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 to 11.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD001860-sec-0130"> <h6 class="title">Azithromycin (single dose) every six months</h6> <p>Three studies compared azithromycin mass treatment every six months with annual treatment (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>). In <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>, the treatment every six months was targeted at children aged 0 to 12 years only. <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> and <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> reported active trachoma, and results were similar between communities treated every six months and communities treated annually. </p> <p> <ul id="CD001860-list-0026"> <li> <p>In <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>, the prevalence of active trachoma at 36 months was 7.8% (95% CI 5.3% to 11.4%) in the communities where children were treated every six months and 8.0% (95% CI 5.0% to 11.6%) in the communities where everyone was treated annually. </p> </li> <li> <p>In <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>, the prevalence of active trachoma in children aged 0 to 9 years at 42 months was 35.0% (95% CI 23.9% to 46.1%) in communities treated every six months compared with 31.5% (95% CI 21.6% to 41.3%) in communities treated annually. The authors reported that they did not detect a difference at all other time points (12, 18, 24, 30, 36 months) in children aged 0 to 9 years nor in people aged 10 years or older. </p> </li> </ul> </p> <p>All three studies reported results for <i>C trachomatis</i> (see <a href="#CD001860-tbl-0018">Table 14</a>). Overall, there was some evidence of lower prevalence of <i>C trachomatis</i> infection in communities treated every six months, but the differences were generally small and not statistically significant. These data were not pooled due to differences in follow‐up and age groups considered and in reporting (mean community prevalences). </p> <div class="table" id="CD001860-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Azithromycin (single‐dose) every 6 months compared with annual treatment: mean community prevalence of infection with C trachomatis </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Intervention: everyone aged 1 year and older offered single‐dose oral azithromycin every 6 months</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator: everyone aged 1 year and older offered single‐dose oral azithromycin annually</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence % </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence %</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a><br/> Children aged 0 to 5 years<br/> Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 to 6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 to 9.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a><br/> Adults aged 15 years or older Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children aged 0 to 9 years  </p> <p>Follow‐up: 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> <br/> Children aged 0 to 9 years<br/> Follow‐up: 24 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 to 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children aged 0 to 9 years<br/> Follow‐up: 36 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.6 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children and adults aged 10 years and older  </p> <p>Follow‐up: 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children and adults aged 10 years and older <br/> Follow‐up: 24 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 to 2.8<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.8<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>  </p> <p>Children and adults aged 10 years and older <br/> Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a><br/> Children aged 1 to 5 years<br/> Follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 21.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> <br/> Children aged 1 to 5 years<br/> Follow‐up: 24 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 to 12.4</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PRET Niger: 24 communities in each group; only children aged 0 to 12 years treated in intervention group.<br/> TANA: 12 communities in each group.<br/> TEF: 8 communities in each group. </p> </div> </div> </section> <section id="CD001860-sec-0131"> <h6 class="title">Annual mass drug administration compared to annual mass drug administration if evidence of trachoma in the community (<i>C trachomatis</i> infection or active trachoma) </h6> <p>In <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> and <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>, annual mass drug administration was also compared to annual mass drug administration if there was evidence of follicular trachoma or infection, that is the lack of infection was to be used as a stopping rule. </p> <p>In <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> the stopping rule was not applied because infection was observed in all communities after dosing. </p> <p>In <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> there was no evidence of any difference according to stopping rule on active trachoma (rate ratio 1.17, 95% CI 0.65 to 1.53) or <i>C trachomatis</i> infection (rate ratio 0.78, 95% CI 0.14 to 4.49) at 36 months, but with wide confidence intervals, indicating considerable uncertainty in the effect estimate. The rate ratios quoted here compare communities allocated to stopping rule, that is that received only one round of mass drug treatment, with communities that received three rounds of mass drug treatment, with confidence intervals adjusted for cluster design. Communities in the stopping‐rule arms only received treatment if there were observed cases of infection or disease in the community in the previous six months, and this rule was implemented for all communities, hence they received only one round of mass drug treatment. </p> </section> <section id="CD001860-sec-0132"> <h6 class="title">Strategies to improve the coverage of mass treatment with azithromycin</h6> <p>In the three PRET studies (<a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>), annual mass drug administration with single dose azithromycin and a standard coverage of 80% to 90% was compared to annual mass drug administration of azithromycin with enhanced coverage of 90% or more. All three studies found little evidence of a benefit of the additional effort to increase the coverage of mass treatment. </p> <p> <ul id="CD001860-list-0027"> <li> <p>In <a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>, the prevalence of <i>C trachomatis</i> infection at 36 months was 7.1% (95% CI 2.7% to 11.4%) in the enhanced‐coverage communities compared with 4.6% (95% CI 0% to 9.5%) in the standard‐coverage communities. </p> </li> <li> <p>In <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> at 36 months (one year after the third mass drug administration), there was no evidence of any difference in the prevalence of <i>C trachomatis</i> infection according to coverage of mass drug administration. The prevalence of infection was 4.0% in the standard‐coverage communities and 5.4% in the enhanced‐coverage communities. The authors reported an adjusted difference of 1.4% (95% CI −1.0% to 3.8%). </p> </li> <li> <p>In <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a>, there was no evidence for an effect of enhanced coverage on <i>C trachomatis</i> infection (rate ratio 1.03, 95% CI 0.18 to 5.89) or active trachoma (rate ratio 1.15, 95% CI 0.74 to 1.79), but with wide confidence intervals, indicating considerable uncertainty in the effect estimate. </p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001860-sec-0133" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001860-sec-0133"></div> <section id="CD001860-sec-0134"> <h3 class="title" id="CD001860-sec-0134">Summary of main results</h3> <p>The trials included in this review provide evidence that individuals with trachoma benefit from antibiotic treatment (<a href="./full#CD001860-tbl-0001">summary of findings Table for the main comparison</a>). Antibiotic treatment reduces the risk of active trachoma and ocular <i>C trachomatis</i> infection up to 12 months after treatment. The trials included in this review were clinically and statistically heterogeneous, and most had serious limitations in their design. This makes it difficult to estimate the size of the effect ‐ the current best guess would be an approximate 20% risk reduction. We judged the certainty of the evidence to be low. Oral and topical treatments appeared to have similar effects if used as prescribed (<a href="./full#CD001860-tbl-0002">summary of findings Table 2</a>). One study compared oral antibiotic and unsupervised topical treatment and found the oral antibiotic to be more effective "under practical operational conditions", which may have been due to poor compliance with the more complex topical treatment regimen (<a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a>). </p> <p>Only three of the more recent trials in individuals used azithromycin, which is the currently recommended oral antibiotic treatment. None of these trials had a no‐treatment group. However, in the individually randomised trials there was no evidence that azithromycin was less effective than topical tetracycline. </p> <p>We identified four community‐based trials comparing azithromycin versus no treatment. These trials were of variable quality and size, however there was one large, good‐quality trial conducted in Ethiopia providing moderate‐certainty evidence that community‐based treatment with a single dose of azithromycin reduces the prevalence of active trachoma and ocular chlamydial infection in children up to 12 months after treatment (<a href="./full#CD001860-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>). </p> <p>Only one trial compared oral versus topical community‐based treatment (<a href="./full#CD001860-tbl-0004">summary of findings Table 4</a>). This study was conducted in three countries in Africa and was therefore included as three separate studies in this review. Data from this study were inconsistent. In The Gambia and Egypt, there was some evidence that oral azithromycin was more effective than topical tetracycline, particularly with regards to ocular infection. However, after adjustment for the cluster design of the study, these findings were not statistically significant and were not replicated consistently in the Tanzanian arm of the study. </p> <p>The included studies considered several different dosing strategies. These fall into three broad categories: applying mass treatment at different dosing intervals; applying cessation or stopping rules to mass treatment; and strategies to increase mass treatment coverage. There was no strong evidence to support any variation in the recommended annual mass treatment.   </p> <p>None of the included trials reported any serious adverse events associated with either of the currently used antibiotics, azithromycin and topical tetracycline. However, for many of the trials it was not clear whether data on adverse effects had been collected systematically. In the one trial that did collect and report these data systematically, between 10% and 15% of people experienced symptoms such as nausea and vomiting with azithromycin treatment. </p> <p>Results from five cluster‐randomised trials of mass treatment with azithromycin provided high‐certainty evidence of an increased risk of resistance of <i>S pneumoniae</i> ,<i>S aureus</i> , and <i>E coli</i> to azithromycin, tetracycline, and clindamycin with risk ratios in the order of 5 at 12 months. There was no evidence to support increased resistance to penicillin or trimethoprim‐sulfamethoxazole (TMP‐SMX). </p> </section> <section id="CD001860-sec-0135"> <h3 class="title" id="CD001860-sec-0135">Overall completeness and applicability of evidence</h3> <p>A strength of the evidence is that the included trials come from many different countries and populations. However, it is unfortunate that heterogeneity between trial results meant that we could not estimate with any confidence the size of the effect for treatment of trachoma with oral or topical antibiotics, although it is likely that both oral and topical treatments have a beneficial effect. </p> <p>The epidemiology of trachoma has changed over time as programmes have implemented the SAFE strategy. In March 2019, the number of people living in areas where the prevalence of trachomatous inflammation–follicular (TF) in children aged 1 to 9 years was ≥ 5% was 142.2 million, down from 1517 million in 2002 (<a href="./references#CD001860-bbs2-0129" title="WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2018. WHO ‐ Weekly Epidemiological Record2019;94(29):317–28. [www.who.int/wer/2018/wer9429/en/] ">WER 2019</a>). The majority of people living in trachoma endemic areas are in sub‐Saharan Africa. Many of the more recent trials included in this review took place in countries in the African Region. The level of endemicity was relatively high in most of these studies, and the extent to which they are applicable in settings with lower endemicity is unclear.  </p> <p>Almost all the trials in individuals were done in children, and the generalisability of these findings to adults is uncertain. Data were reported for adults and children in the community‐based trials. Given the small number of trials, it was not possible to determine whether the effects are different in these groups, but one study provided data on ocular infection after mass treatment in both children and adults (<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>). The observed risk ratio was 0.32 (95% CI 0.26 to 0.40) in children and 0.49 (95% CI 0.33 to 0.71) in adults. </p> <p>Where azithromycin is not donated, there is a major cost difference between topical tetracycline and oral azithromycin, but it was not possible to determine which is the more cost‐effective strategy per extra case cured. </p> <p>Some populations in which trachoma is endemic are subject to migration, which may account in part for the low follow‐up rates in the community trials; it may also have implications in determining the most effective treatment in those populations where new infected cases migrate into the community. </p> </section> <section id="CD001860-sec-0136"> <h3 class="title" id="CD001860-sec-0136">Quality of the evidence</h3> <p>The included trials were published from 1966 onwards, and their quality was variable. The certainty of evidence for most outcomes was low, particularly for the comparison of antibiotics versus no treatment (<a href="./full#CD001860-tbl-0001">summary of findings Table for the main comparison</a>). Reporting of sequence generation and allocation concealment was not good, and it was often difficult to assess the effect of incomplete data due to inadequate reporting. There was considerable heterogeneity of results. However, masking of outcome assessment was reported for laboratory analyses (less so for clinical assessments of active trachoma), and there was little evidence of selective outcome reporting. There was moderate‐certainty evidence for the comparison of oral versus topical antibiotics for the outcome active trachoma (<a href="./full#CD001860-tbl-0002">summary of findings Table 2</a>). </p> <p>The community‐based trials were also of variable methodological quality (<a href="./full#CD001860-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001860-tbl-0004">summary of findings Table 4</a>). In some cluster‐randomised studies, only two communities were randomly allocated to treatment. Although adjustment for baseline characteristics can alleviate this problem to some extent, the interpretation of these studies remains problematic. As well as being underpowered, it is difficult to exclude the alternative explanation that there is some characteristic that is different between the communities (apart from treatment of trachoma) and which may be the real cause of any observed differences in outcome. There was also little information on other potential sources of bias in cluster‐randomised trials such as recruitment bias. </p> <p>Four community‐based trials had a 'delayed treatment' design that involved randomly selecting clusters for treatment and comparing the prevalence of trachoma 12 months after treatment with a random selection of untreated clusters, which are then enrolled in the treatment programme (<a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a>; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a>; <a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a>). This study design overcomes the ethical dilemma of surveying communities for trachoma and then withholding treatment for 12 months, but has the disadvantage that baseline data on trachoma are not available in the control group. </p> </section> <section id="CD001860-sec-0137"> <h3 class="title" id="CD001860-sec-0137">Potential biases in the review process</h3> <p>This review has been substantially revised for the update. New methods, such as assessment of risk of bias and subgroup and sensitivity analyses, and inclusion of antimicrobial resistance as an outcome, have been incorporated. A new protocol was not written. It is possible that the update could have been influenced by knowledge of the trial results. </p> <p>We found the classification <a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> problematic. In the last edition of this review we included this trial in the comparison "azithromycin versus no treatment" but on re‐evaluation for the current edition we considered the trial to be "azithromycin versus tetracycline". Although the study was described as azithromycin versus no azithromycin in fact people with active trachoma in the control group received tetracycline. The change in classification of this study did not affect the conclusions of this review. </p> <p>In the current 2019 update we included studies that compared different treatment strategies. We added in the additional question to our objectives: "What is the effect of annual versus different treatment frequencies?". We did not repeat the searches for this additional question. There may be studies that were not included in previous editions of the review (for example <a href="./references#CD001860-bbs2-0082" title="SchemannJF , GuinotC , TraoreL , ZefackG , DembeleM , DialloI , et al. Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub‐Saharan African country, Mali. Acta Tropica2007;101(1):40‐53. ">Schemann 2007</a>), that would have been eligible for the current update. We do not anticipate that we will have missed many relevant studies as searches were screened from 2010 onwards. </p> </section> <section id="CD001860-sec-0138"> <h3 class="title" id="CD001860-sec-0138">Agreements and disagreements with other studies or reviews</h3> <p>We identified a number of non‐randomised studies providing data on antimicrobial resistance. Their results are summarised in <a href="#CD001860-tbl-0019">Table 15</a>. Overall, the non‐randomised studies provided inconsistent evidence on resistance, with some evidence of increased resistance to azithromycin for <i>S pneumoniae.</i> Three studies considered resistance in <i>C trachomatis</i> after mass treatment and suggest little evidence of resistance to azithromycin. </p> <div class="table" id="CD001860-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Antimicrobial resistance in non‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Citation and location</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0124" title="SolomonAW , MohammedZ , MassaePA , ShaoJF , FosterA , MabeyDC , et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy2005;49(11):4804‐6. ">Solomon 2005</a> </p> <p>Rombo district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in people with <i>C trachomatis</i> infection. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>956/978 residents examined at baseline; 56 with eye infection; 43 isolates from these people at baseline. </p> <p>“We conclude that no</p> <p>clinically or programmatically significant changes in C. trachomatis</p> <p>azithromycin or tetracycline susceptibilities were induced"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0115" title="HongKC , SchachterJ , MoncadaJ , ZhouZ , HouseJ , LietmanTM . Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerging Infectious Diseases2009;15(7):1088‐90. ">Hong 2009</a> </p> <p>Gurage zone, Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Samples taken before and after treatment.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months after 4 bi‐annual mass treatment (2 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Found no significant differences in susceptibilities to azithromycin and doxycycline in 6 post‐treatment and 4 pre‐treatment samples </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0131" title="WestSK , MoncadaJ , MunozB , MkochaH , StoreyP , HardickJ , et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?. Journal of Infectious Diseases2014;210(1):65‐71. ">West 2014</a> </p> <p>Kongwa district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isolates obtained before and after mass drug administration.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months after 3 years of mass treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared resistance to <i>C trachomatis</i> in children with/without continuing infection and found similar levels of resistance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>S pneumoniae</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0117" title="LeachAJ , Shelby‐JamesTM , MayoM , GrattenM , LamingAC , CurrieBJ , et al. A prospective study of the impact of community‐based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clinical Infectious Diseases1997;24(3):356‐62. ">Leach 1997</a> </p> <p>Northern territory (Aboriginal community), Australia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children with trachoma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Erythromycin</p> <p>(results not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks, 2 months, and 6 months following azithromycin treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 children with trachoma:</p> <p> <ul id="CD001860-list-0028"> <li> <p>1/79 resistant before treatment;</p> </li> <li> <p>6/38 at 2 to 3 weeks;</p> </li> <li> <p>10/37 at 6 months.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0107" title="FryAM , JhaHC , LietmanTM , ChaudharyJS , BhattaRC , ElliottJ , et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clinical Infectious Diseases2002;35(4):395‐402. ">Fry 2002</a> </p> <p>Western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Penicillin</p> <p>Chloramphenicol</p> <p>Sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 180 days, 5% of 104 children with 2 previous treatments carriage of azithromycin‐resistant <i>S pneumoniae</i> compared with 0% of children with 1 (150 children) or 0 (149 children) previous treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0093" title="BattSL , CharalambousBM , SolomonAW , KnirschC , MassaePA , SafariS , et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic‐resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy2003;47(9):2765‐9. ">Batt 2003</a> </p> <p>Rombe district, northern Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Penicillin</p> <p>Erythromycin</p> <p>Cotrimoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"At the 2‐month and 6‐month points, macrolide‐resistant isolates were 0% and 1%, respectively"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0109" title="GaynorBD , HolbrookKA , WhitcherJP , HolmSO , JhaHC , ChaudharyJS , et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. British Journal of Ophthalmology2003;87(2):147‐8. ">Gaynor 2003</a> </p> <p>Western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 1 year after mass distribution of azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Trimethoprim/sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No macrolide resistance observed in 50 nasopharyngeal samples positive for <i>S pneumoniae</i>. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0110" title="GaynorBD , ChidambaramJD , CevallosV , MiaoY , MillerK , JhaHC , et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. British Journal of Ophthalmology2005;89(9):1097‐9. ">Gaynor 2005</a> </p> <p>Kailali district, western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 6 months after the 3rd annual treatment with azithromycin or tetracycline or no treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Trimethoprim/sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/163 (3%) isolates were resistant to azithromycin in the azithromycin‐treated communities compared with 0 in 126 children in tetracycline‐treated communities and 91 in untreated. Tetracycline resistance was higher in tetracycline‐treated communities (39/126, 31%) compared with 17% and 16% in azithromycin‐treated and untreated communities, respectively. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0094" title="BlochEM , WestSK , MabulaK , WeaverJ , MrangoZ , MunozB , et al. Antibiotic resistance in young children in kilosa district, Tanzania 4 years after mass distribution of azithromycin for trachoma control. American Journal of Tropical Medicine and Hygiene2017;97(3):815‐8. ">Bloch 2017</a> </p> <p>KIlosa district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 4 years after mass distribution of azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month to 59 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance to azithromycin was observed in 14.3%, 29.0%, and 16.6% of the <i>S pneumoniae</i> , <i>S aureus</i> , and <i>E coli</i> isolates, respectively. </p> </td> </tr> </tbody> </table> </div> <p>A recent systematic review of community‐level interventions in reducing the prevalence of active trachoma (published as an abstract only) identified a similar number of trials as the current review and came to similar conclusions, that is that mass drug administration reduces active trachoma and ocular chlamydia infection (<a href="./references#CD001860-bbs2-0095" title="BobbaS , PhelanS , SchierhoutG , McManusH , MenziesR , KaldorJ . A systemic review of community level interventions in reducing the prevalence of active trachoma. Clinical and Experimental Ophthalmology2018;46(Suppl 1):90. ">Bobba 2018</a>). <a href="./references#CD001860-bbs2-0103" title="DiabMM , AllenRC , GawdatTI , SaifAS . Trachoma elimination, approaching 2020. Current Opinion in Ophthalmology2018;29(5):451‐7. ">Diab 2018</a> concluded that azithromycin eye drops twice daily for three days may be as efficient as oral azithromycin in treating active trachoma. This was largely based on the findings of a non‐randomised study, but the authors did identify the one trial on this topic identified in the current review (<a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>). We agree that the trial identified similar rates of cure over 60 days, but suggest that confirmatory studies are needed to assess longer‐term follow‐up. </p> <p>A recent systematic review of resistance following mass azithromycin distribution drew similar conclusions to the current review (<a href="./references#CD001860-bbs2-0119" title="O'BrienKS , EmersonP , HooperPJ , ReingoldAL , DennisEG , KeenanJD , et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infectious Diseases2019;19(1):e14‐25. ">O'Brien 2019</a>), that is that the available evidence suggests that macrolide resistance to azithromycin is increased after mass azithromycin distribution, particularly for <i>S pneumoniae.</i> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001860-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD001860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 1 Active trachoma at 3 months." data-id="CD001860-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 1 Active trachoma at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 2 Active trachoma at 12 months." data-id="CD001860-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 2 Active trachoma at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 3 Active trachoma at 3 months (subgroup analysis)." data-id="CD001860-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 3 Active trachoma at 3 months (subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 4 Active trachoma at 12 months (subgroup analysis)." data-id="CD001860-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 4 Active trachoma at 12 months (subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 5 Ocular C trachomatis infection at 3 months." data-id="CD001860-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 5 Ocular <i>C trachomatis</i> infection at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 6 Ocular C trachomatis infection at 12 months." data-id="CD001860-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 6 Ocular <i>C trachomatis</i> infection at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 7 Ocular C trachomatis infection at 3 months (subgroup analysis)." data-id="CD001860-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 7 Ocular <i>C trachomatis</i> infection at 3 months (subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any antibiotic versus control (individuals), Outcome 8 Ocular C trachomatis infection at 12 months (subgroup analysis)." data-id="CD001860-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Any antibiotic versus control (individuals), Outcome 8 Ocular <i>C trachomatis</i> infection at 12 months (subgroup analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus topical antibiotics (individuals), Outcome 1 Active trachoma at 3 months." data-id="CD001860-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral versus topical antibiotics (individuals), Outcome 1 Active trachoma at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus topical antibiotics (individuals), Outcome 2 Active trachoma at 12 months." data-id="CD001860-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oral versus topical antibiotics (individuals), Outcome 2 Active trachoma at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus topical antibiotics (individuals), Outcome 3 Ocular C trachomatis infection at 3 months." data-id="CD001860-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oral versus topical antibiotics (individuals), Outcome 3 Ocular <i>C trachomatis</i> infection at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral versus topical antibiotics (individuals), Outcome 4 Ocular C trachomatis infection at 12 months." data-id="CD001860-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oral versus topical antibiotics (individuals), Outcome 4 Ocular <i>C trachomatis</i> infection at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 1 Active trachoma at 3 months." data-id="CD001860-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 1 Active trachoma at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 2 Active trachoma at 12 months." data-id="CD001860-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 2 Active trachoma at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 3 Ocular C trachomatis infection at 3 months." data-id="CD001860-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 3 Ocular <i>C trachomatis</i> infection at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 4 Ocular C trachomatis infection at 12 months." data-id="CD001860-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 4 Ocular <i>C trachomatis</i> infection at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral azithromycin versus control (communities), Outcome 1 Active trachoma at 12 months." data-id="CD001860-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Oral azithromycin versus control (communities), Outcome 1 Active trachoma at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oral azithromycin versus control (communities), Outcome 2 Ocular C trachomatis infection at 12 months." data-id="CD001860-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Oral azithromycin versus control (communities), Outcome 2 Ocular <i>C trachomatis</i> infection at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 1 Active trachoma at 3 months." data-id="CD001860-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 1 Active trachoma at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 2 Active trachoma at 12 months." data-id="CD001860-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 2 Active trachoma at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 3 Ocular C trachomatis infection at 3 months." data-id="CD001860-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 3 Ocular <i>C trachomatis</i> infection at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001860-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/urn:x-wiley:14651858:media:CD001860:CD001860-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_t/tCD001860-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 4 Ocular C trachomatis infection at 12 months." data-id="CD001860-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 4 Ocular <i>C trachomatis</i> infection at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/media/CDSR/CD001860/image_n/nCD001860-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001860-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic versus control for trachoma: individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antibiotic versus control for trachoma: individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> people resident in a trachoma endemic area<br/> <b>Intervention:</b> antibiotics, including (oxy)tetracycline, doxycycline, sulfonamides<br/> <b>Comparison:</b> control (no treatment or placebo) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Active trachoma</b> </p> <p>Clinical assessment: active trachoma defined as TF, TI, or both<br/>   </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> <br/> (0.69 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1961<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b><br/> (552 to 712) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.74</b> <br/> (0.55 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1035<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>555 per 1000</b><br/> (413 to 750) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b> </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> <br/> (0.63 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>297<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b><br/> (315 to 520) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.25</b> <br/> (0.08 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/> (16 to 156) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>4 studies made no comment on adverse effects. </p> <p>3 studies noted no untoward reactions (sulfonamides) or only trivial reactions (tetracycline, sulfonamide). </p> <p>1 study of 155 students noted 3 adverse reactions to sulfonamide (severe purpura associated with marked thrombocytopenia, 2 cases of drug rash). </p> <p>1 study of 122 children noted anorexia, nausea, vomiting, or diarrhoea in 3 children. 2 of these children were receiving doxycycline, and the disturbances lasted only a single day in each child, in spite of continuing medication. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1961<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; three studies at high risk of attrition bias) and one level for serious inconsistency (risk ratios ranged from 0.40 to 1.02 and I<sup>2</sup> = 73%).<br/> <sup>2</sup>Downgraded one level for serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; two studies at high risk of attrition bias) and one level for serious inconsistency: risk ratios ranged from 0.50 to 1.05 and  I<sup>2</sup> = 90%). We did not additionally downgrade for imprecision, although the upper confidence interval was 1.00, as we felt that this imprecision probably reflects limitations in study design and inconsistency.<br/> <sup>3</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported; two studies at high risk of attrition bias) and one level for serious imprecision (95% CI 0.63 to 1.04 include null effect 1).<br/> <sup>4</sup>Downgraded two levels for very serious limitations in study design (only one small study with poorly reported methods of sequence generation and allocation concealment and which did not mask outcome assessment).<br/> <sup>5</sup>Downgraded one level for very serious limitations in study design (methods of sequence generation, allocation concealment, and masking poorly reported; three studies at high risk of attrition bias) and one level for imprecision, as the studies were not large enough to assess rare adverse events.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antibiotic versus control for trachoma: individuals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001860-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral versus topical antibiotic for trachoma: individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Oral versus topical antibiotic for trachoma: individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> people resident in a trachoma endemic area<br/> <b>Intervention:</b> oral antibiotic, including azithromycin, doxycycline, sulfamethoxypyridazine, and sulfadimethoxine<br/> <b>Comparison:</b> topical antibiotic, including tetracycline and sulfafurazole </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical antibiotic</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Active trachoma</b> </p> <p>Clinical assessment: active trachoma defined as TF, TI, or both</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97 </b><br/> (0.81 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>953<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>600 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>582 per 1000</b><br/> (486 to 696) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> <br/> (0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>886<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b><br/> (375 to 575) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b> </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooled estimate due to high heterogeneity: <a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> RR 6.05 (95% CI 0.78, 46.95); <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> RR 0.57 (0.14, 2.30); <a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> RR 1.30 (0.41, 4.11) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> RR 2.59 (95% CI 0.28, 23.88); <a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> RR 0.50 (0.18, 1.43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>3 studies made no comment on adverse effects.</p> <p>1 study of 155 students noted 3 adverse reactions to sulfonamide (severe purpura associated with marked thrombocytopenia, 2 cases of drug rash). </p> <p>1 study of 194 people reported abdominal pain more often in azithromycin group (26% versus 16%, P = 0.09). Other effects: diarrhoea, vomiting, fever, headache, body pain were  similar between 2 study groups.  </p> <p>1 study of 60 people reported no serious adverse reactions and that both azithromycin and tetracycline were well tolerated.   </p> <p>1 study of 168 children noted that azithromycin was well tolerated and that only 2 children (of 125 treated) complained of nausea. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1583<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (only one study reported adequate methods for allocation concealment and masking of outcome assessment) and one level for inconsistency (study estimates ranged from 0.65 to 1.37 and I<sup>2</sup> = 63%).<br/> <sup>2</sup>Downgraded one level for serious limitations in study design (only one study reported adequate methods for allocation concealment and masking of outcome assessment) and one level for inconsistency (study estimates ranged from 0.66 to 1.15 and I<sup>2</sup> = 56%).<br/> <sup>3</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported, one study at high risk of attrition bias) and two levels for very serious inconsistency (see comment column in table).<br/> <sup>4</sup>Downgraded one level for serious limitations in study design (methods of sequence generation and allocation concealment poorly reported, one study at high risk of attrition bias); one level for serious inconsistency (see comment column in table); and one level for imprecision (only 16 events in total).<br/> <sup>5</sup>Downgraded one level for serious limitations in study design (none of the trials reported adequate methods of allocation concealment and masking of outcome assessment, and adverse effects were not consistently considered and reported) and one level for imprecision (individual studies were underpowered to assess rare effects).  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral versus topical antibiotic for trachoma: individuals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001860-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral azithromycin compared to control for trachoma: communities</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral azithromycin compared to control for trachoma: communities</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> communities in a trachoma endemic area<br/> <b>Intervention:</b> oral azithromycin<br/> <b>Comparison:</b> control (no treatment) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence (GRADE)<br/>  </b> </p> </td> <td align="left" class="table-header" colspan="0" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Active trachoma</b><br/> Clinical assessment: active trachoma defined as TF, TI, or both </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.58</b> </p> <p>(0.52 to 0.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1247<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <b>moderate</b><sup>1</sup><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="4" valign="top"> <p>One additional study reported data as median community prevalence. At 12 months, the median community prevalence of active trachoma was 9.3% in communities given one single dose of azithromycin (range 0 to 38.9%) and 8.2% in communities that had not been treated (range 0 to 52.9%). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>(52 to 65)</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> </p> <p>(156 to 195)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Ocular <i>C trachomatis</i> infection</b><br/> Follow‐up: 3 months </p> <p>Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.36 </b><br/> (0.31 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2139</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝ <b>moderate</b><sup>2</sup><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/> (31 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (93 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There was evidence of an increased risk of resistance of <i>S pneumoniae</i> , <i>S aureus</i> , and <i>E coli</i> to azithromycin, tetracycline, and clindamycin with risk ratios in the order of 5 at 12 months. No evidence to support increased resistance to penicillin or trimethoprim/sulfamethoxazole. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1354</p> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <b>high</b><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No serious adverse events reported. Azithromycin associated with reduced mortality in children. Main adverse effect of azithromycin (in approximately 10% of the population) was abdominal pain, vomiting, and nausea. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3069<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕ <b>high</b><br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="0" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> (medium/high risk) were based on prevalence estimates used as the basis for recommendations as set out in <a href="./references#CD001860-bbs2-0134" title="World Health Organization. Report of the 3rd global scientific meeting on trachoma. www.who.int/trachoma/resources/who_pbd_2.10/en/. ">WHO 2010</a>. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious inconsistency.<br/> <sup>2</sup>Downgraded one level for serious inconsistency: I<sup>2</sup> = 79%. However, both study estimates were in the same direction 0.32 (0.26 , 0.40) and 0.49 (0.36 , 0.68). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral azithromycin compared to control for trachoma: communities</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001860-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral azithromycin compared to topical tetracycline for trachoma: communities</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Oral azithromycin compared to topical tetracycline for trachoma: communities</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> people (any age) with active trachoma<br/> <b>Settings:</b> communities in a trachoma endemic area<br/> <b>Intervention:</b> oral azithromycin<br/> <b>Comparison:</b> topical tetracycline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical tetracycline</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Oral azithromycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Active trachoma</b><br/> Clinical assessment: active trachoma defined as TF, TI, or both </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.52 (95% CI 0.43, 0.64); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.16 (1.00, 1.36); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.76 (0.50, 1.15) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5414<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.74 (95% CI 0.61, 0.90); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.19 (1.02, 1.40); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.55 (0.40, 0.75) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocular <i>C trachomatis infection</i> </b><br/> Positive test for <i>C trachomatis</i> infection identified by culture, staining on conjunctival smears, or nucleic acid amplification methods </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5773<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.22 (95% CI 0.11, 0.44); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 0.68 (0.49, 0.95); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.51 (0.37, 0.70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5276<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> RR 0.48 (95% CI 0.31, 0.74); <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> RR 1.01 (0.76, 1.35); <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> RR 0.62 (0.44, 0.87) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic resistance</b> </p> <p>Proportion of samples showing evidence of resistance to antibiotic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies addressed this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Any time point</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No comment on adverse effects in study reports</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>TF:</b> trachomatous inflammation‐follicular; <b>TI:</b> trachomatous inflammation‐intense; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence<br/> High‐certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate‐certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low‐certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low‐certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious limitations in study design (three cluster‐randomised trials, two of which only randomised two communities to oral/topical antibiotic; assessment of trachoma was not masked, but assessment of ocular infection was; recruitment bias not addressed and problems with incomplete outcome data; some attempt made to adjust for baseline imbalances) and one level for serious inconsistency (results were different in the different studies ‐ see comment column in table). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oral azithromycin compared to topical tetracycline for trachoma: communities</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individually randomised studies: participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sex</b> </p> <p><b>% male</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma or "undetermined case"<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months to 60 years<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51%<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months to 10 years<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Guinea and Pakistan<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐school</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38% </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian reservation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian reservation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 21 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian boarding school)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 to 20 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (Indian boarding school)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia (Aboriginal children)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>641</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 13 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saudi Arabia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active trachoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary school age</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*<a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> and <a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> were reported in the same paper. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individually randomised studies: participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Individually randomised studies: comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Studies with a no‐treatment, placebo, or inactive treatment comparator group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline derivative GS2989 (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once every school day for 11 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a>** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 7 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>vitamin pills</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 6 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>daily for 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once a month for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 4.0 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week up to 28 doses in 40 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week up to 28 doses in 40 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a>*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfafurazole (topical) + sulfadimethoxine (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15%/100 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days every month for 5 months/bi‐weekly for 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days every month for 5 months/bi‐weekly for 5 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a>; </p> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trisulfapyrimidines (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5 g/day (in 3 doses)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 consecutive days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral versus topical antibiotic</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once or weekly for 3 weeks or monthly for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline/polymyxin + oral placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oxytetracycline 1%/polymyxin 10,000 units/gram</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 28 days for 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a>; <a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sulfamethoxypyridazine (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 g</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 5 consecutive days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every week for 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 times daily on 5 consecutive days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a>**** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (topical)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice daily for 2 days</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin (oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>*Also compared to oxytetracycline (Terramycin) once every school day for 11 weeks.<br/> **Also compared to doxycycline (oral) 5 mg/kg single dose every month for 12 months.<br/> ***Also compared to sulfadimethoxine (oral) 100 mg/kg bi‐weekly or weekly dose for 5 months and sulfafurazole (topical) 15% twice daily for 5 consecutive days, every month for 5 months.<br/> ****Also compared to azithromycin (topical) 1.5% twice daily for 3 days. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Individually randomised studies: comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Individually randomised studies: outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Active trachoma</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Ocular infection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Classification scheme</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laboratory assessments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO 1962</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (26 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IDEIA amplified enzyme‐linked immunosorbent assay (Dako) for genus‐specific lypopolysaccharide antigen </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (26 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (6 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (2 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival swab analysed using PCR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modification of Dawson 1975</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs followed by culture in irradiated McCoy cells</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (4 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacCallan 1936</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MacCallan 1936</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (20 weeks)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival specimens; slides stained with direct fluorescent antibody for chlamydial elementary bodies </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thygeson 1960</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1969</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFAT on scrapings of upper tarsal conjunctival epithelium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 1 follicle or some papillary hypertrophy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO 1962</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓ (5 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival scrapings for inclusion bodies/cells/organisms/mucus; IFAT for free elementary bodies </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No follow‐up</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified McCallan classification</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>IFAT: immunofluorescence antibody test<br/> PCR: polymerase chain reaction </p> <p>*Followed up to three years.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Individually randomised studies: outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Cluster‐randomised studies: participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Inclusion criteria: communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Inclusion criteria: people</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of communities randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of people randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Sex % male</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Endemicity</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Children</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages: no active trachoma (64%);<br/> mild follicular inflammatory (F1, P1, P2) (16%); follicular trachoma (F2, F3) (14%); severe inflammatory trachoma (P3) (6%)<br/> Prevalence of ocular infection (LCR‐positive) (36%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3261</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All ages: no active trachoma (47%); mild follicular inflammatory (F1, P1, P2) (22%); follicular trachoma (F2, F3) (15%); severe inflammatory trachoma (P3) (16%)<br/> Prevalence of ocular infection (LCR‐positive) (19%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma endemic areas</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (pair‐matched)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1753</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma among 0 to 9 year olds (36%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No active trachoma (57%); mild follicular inflammatory (F1, P1, P2) (27%); follicular trachoma (F2, F3) (9%); severe inflammatory trachoma (P3) (7%)<br/> Prevalence of ocular infection (LCR‐positive) (36%)<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vietnam</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>randomly selected from Thanh Hoa Province</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community older than 6 months was assessed for trachoma and people with trachoma and their household members treated. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1851</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months or older</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma: <br/> 5 to 15 years (6%)<br/> less than 5 years (2%)<br/> <br/> Prevalence of <i>C trachomatis</i> infection:   <br/> 5 to 15 years (16%)<br/> less than 5 years (17%)<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma: <br/> 15 years and above (8%)<br/> <br/> Prevalence of <i>C trachomatis</i> infection: <br/> 15 years and above (8%)<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 15% prevalence of active trachoma in children</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>average age 18 to 19 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection (all ages) (7%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>population between 250 and 600 and prevalence of 10% or more of active trachoma in children aged 0 to 60 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,991</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children aged 0 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of ocular <i>C trachomatis</i> infection in children aged 5 years or younger (approximately 20%)<br/> <br/> Prevalence of TF in children aged 5 years or younger (25% to 30%) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of TF in people aged 15 years or older (approximately 1%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>less than 5000 people with an estimated active trachoma prevalence of between 20% and 50% for mesoendemic communities and less than 20% for hypoendemic communities </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children aged 0 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% to 52%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged less than 5 years ranged from 18% to 25%.<br/> <br/> Prevalence of TF in children aged less than 5 years was 30%. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection (all ages) (6%)<br/> <br/> Prevalence of TF (all ages) (12%) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>trachoma prevalence greater than 5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel children 5 years or less</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged 5 years or younger was 1%.<br/> <br/> Prevalence of TF in children aged 5 years or younger was 6%. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mali</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2 with interventions relevant to this review)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of active trachoma ranged from 15% to 22% (all ages).</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all subkebeles (geographical unit with approximately 1400 people) in the study region that were less than<br/> a 3‐hour walk from the farthest point that could be reached with a 4‐wheel drive vehicle </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66,404</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel group of children and adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>˜51%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged less than 10 years ranged from 8% to 62% (mean approximately 40%). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in people aged 10 years or older ranged from 2% to 28% (mean approximately 15%).<br/> <br/> Prevalence of active trachoma (all ages) was between 69% and 77%. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>random sample of peasant associations (standardised administrative unit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>everyone present in the community</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5410</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>all ages; sentinel groups of children aged 1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prevalence of <i>C trachomatis</i> infection in children aged 1 to 5 years ranged from 31% to 65% (mean approximately 43%). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not been treated with azithromycin since 2009 and were predicted from prior prevalence surveys to have TF between 5 and 9.9% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not clearly stated but assumed to be everyone in community apart from pregnant women and children under 6 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months or older, only sample of 20 children aged 1 to 9 years assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48% (in children assessed)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> Prevalence of C<i>trachomatis</i> infection in children aged 1 to 9 years ranged from 0 to 33%, median 0%.<br/> <br/> Prevalence of TF in children aged 1 to 9 years ranged from 0 to 62%, median 5% </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>.‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>LCR: ligase chain reaction <br/> TF: trachomatous inflammation–follicular </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Cluster‐randomised studies: participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Cluster‐randomised studies: comparisons</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Studies with a no‐treatment or delayed‐treatment comparator group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline **</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every month for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once only; annually for 3 years; twice a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 3 months for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>delayed treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Studies of azithromycin versus tetracycline</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a>*** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once a week for 3 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>once daily for 6 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a>**** </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>single dose at baseline and 12 months.</p> <p>Non‐index cases received tetracycline, and surgery offered where appropriate.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All patients with active trachoma received topical tetracycline and surgery offered where appropriate. </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Studies of different frequencies of azithromycin</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>for 1 month (Day 0 and Day 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>; <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years (enhanced coverage)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years (standard coverage)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a>;***** <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>twice a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a>; <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>annually for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>cessation rule</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*Azithromycin was given as a single oral dose at 20 mg/kg up to 1 g (adults); tetracycline was given topically 1%.<br/> **One drop four times daily for seven days.<br/> ***Once a week for three weeks.<br/> ****Treatment of people with active trachoma and their household members only.<br/> *****Only children were treated twice yearly. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Cluster‐randomised studies: comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cluster‐randomised studies: outcomes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active trachoma</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ocular infection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resistance</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 14 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dawson 1981</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using LCR.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctival swabs assessed using nucleic acid amplification test.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lytA+<br/> ermB–/mefA/E–<br/> ermB+/mefA/E–<br/> ermB–/mefA/E+<br/> ermB+/mefA/E+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>E coli</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae<br/> S aureus</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>No laboratory tests</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not reported</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i><br/> mefA+/ermB2<br/> mefA+/ermB+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction (Amplicor‐PCR).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thylefors 1986</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjuctival samples analysed using polymerase chain reaction.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Not studied</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported (no serious adverse events)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>LCR: ligase chain reaction<br/> PCR: polymerase chain reaction </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cluster‐randomised studies: outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects: individually randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic (number of people treated)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Report</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0005" title="AttiahMA , elKohlyAM . Clinical assessment of the comparative effect of Terramycin and GS 2989 in the mass treatment of trachoma. International Review of Trachoma1973;50(3):11‐20. ">Attiah 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline (77)</p> <p>Tetracycline derivative GS2989 (75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0006" title="BaileyRL , ArullendranP , WhittleHC , MabeyDC . Randomised controlled trial of single‐dose azithromycin in treatment of trachoma. Lancet1993;342(8869):453‐6. ">Bailey 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (97)</p> <p>Topical tetracycline with oral erythromycin in severe cases (97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Table 2 on page 454 reports adverse effects. Abdominal pain reported more often in azithromycin group (26% versus 16%, P = 0.09). Other effects: diarrhoea, vomiting, fever, headache, body pain, other similar between study groups. </p> <p>"There were no serious adverse reactions and both treatments were well tolerated. All symptoms resolved spontaneously and none required treatment." 1 study participant died, probably due to malaria. He had received topical tetracycline. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0007" title="BowmanRJ , SillahA , vanDebnC , GoodeV , MuquitM , JohnsonGJ , et al. Operational comparison of single‐dose azithromycin and topical tetracycline for trachoma. Investigative Ophthalmology and Visual Science2000;41(13):4074‐9. ">Bowman 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (160)</p> <p>Tetracycline (154)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0008" title="CochereauI , GoldschmidtP , GoepoguiA , AfghaniT , DelvalL , PouliquenP , et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double‐masked clinical trial. British Journal of Ophthalmology2007;91(5):667‐72. ">Cochereau 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin topical 2‐day regimen (222) 3‐day (220) and oral azithromycin (214)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ocular adverse events were reported in 10.8%, 8.9% and 13.1% of patients in the 2‐day, 3‐day and oral treatment groups respectively. Systemic adverse events were reported in 2.6%, 10.2% and 9.0% of patients. None of the adverse events were treatment‐related events. One patient (3‐day group) had a serious unrelated adverse events (death due to head injury)." (page 670) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0009" title="DarougarS , JonesBR , ViswalingamN , PoirierRH , AllamiJ , HoushmandA , et al. Family‐based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. British Journal of Ophthalmology1980;64(4):291‐5. ">Darougar 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxycycline (44)</p> <p>Oxytetracycline (38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 &amp; 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0010" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Sherman</a> </p> <p><a href="./references#CD001860-bbs2-0011" title="DawsonCR , HannaL , WoodTR , ColemanV , BrionesOC , JawetzE . Controlled trials with trisulfapyrimidines in the treatment of chronic trachoma. Journal of Infectious Diseases1969;119(6):581‐90. ">Dawson 1969 Stewart</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trisulfapyrimidines (33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No untoward reactions to sulfonamides were noted" (page 587)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0012" title="DawsonCR , SchachterJ , SallamS , ShetaA , RubinsteinRA , WashtonH . A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clinical Infectious Diseases1997;24(3):363‐8. ">Dawson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline/polymyxin (43)</p> <p>Azithromycin (125)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"In this trial, azithromycin was well tolerated and only two children (of 125 treated) complained of nausea" (page 367) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0013" title="FosterSO , PowersDK , ThygesonP . Trachoma therapy: a controlled study. American Journal of Ophthalmology1966;61(3):451‐5. ">Foster 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfamethoxypyridazine (112)</p> <p>Tetracycline (106)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"3/155 students who received sulfamethoxypyridazine had adverse reactions to the drug. One girl developed a severe purpura associated with marked thrombocytopenia. She recovered following withdrawal of the drug and administration of corticosteroids. Two cases of diagnosed drug rash necessitated discontinuance of the drug. The nephrotic syndrome developed in one boy three months after completion of sulphonamide therapy, but the relationship of this development to therapy was not determined. No reactions or rashes occurred in the other two treatment groups" (page 453) (note: Table 3/Table 4 report 112 children treated with sulfamethoxypyridazine) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0014" title="HoshiwaraI , OstlerHB , HannaL , CignettiF , ColemanVR , JawetzE . Doxycycline treatment of chronic trachoma. JAMA1973;224(2):220‐3. ">Hoshiwara 1973</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxycycline (49)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Anorexia, nausea, vomiting or diarrhea occurred in three children between the 15th and 25th days of medication. Two of these children were receiving doxycycline, and the disturbances lasted only a single day in each child, in spite of continuing medication. Between day 21 and 28 of medication, transient macular rashes and one‐day illness with low‐grade fever and anorexia occurred in four children. Two of them had received drug, and two placebo. It is likely that an intercurrent, unrelated illness was responsible. Gross enamel dysplasia or tooth discoloration was not observed on examination 20 weeks after the end of medication." (page 222) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0016" title="PeachH , PiperS , DevanesenD , DixonB , JeffriesC , BraunP , et al. Northern Territory trachoma control and eye health committee's randomised controlled trial of the effect of eye drops and eye washing on follicular trachoma among aboriginal children. Annual Report of the Menzies School of Health Research. 1986:74‐6. ">Peach 1986</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline (932)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0021" title="ShuklaBR , NemaHV , MathurJS , NathK . Gantrisin and madribon in trachoma. British Journal of Ophthalmology1966;50(4):218‐21. ">Shukla 1966</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfafurazole (140)</p> <p>Sulfadimethoxine (161)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0022" title="TabbaraKF , Abu el AsrarA , al OmarO , ChoudhuryAH , al FaisalZ . Single‐dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology1996;103(5):842‐6. ">Tabbara 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (31)</p> <p>Tetracycline (29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No adverse effects were noted" (page 844); and "The safety of a single oral dose of azithromycin has been demonstrated in this study. Similar to other clinical studies, no adverse effects developed in any of the patients in the azithromycin group" (page 845) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0026" title="WoolridgeRL , ChengKH , ChangIH , YangCY , HsuTC , GraystonJT . Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. American Journal of Ophthalmology1967;63 Suppl(5):1577‐86. ">Woolridge 1967</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline (726)</p> <p>Sulfonamide (526)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No more than trivial reactions were observed in any of these three studies, to vaccine, to oil adjuvant, to eye ointment or to sulfa drug." (page 1581) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse effects: individually randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Studies reporting antibiotic resistance: characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age of participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteria or genetic determinant</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Carriage body reservoir</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample type</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. "><b>PRET Niger</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Niger (Matameye district in the Zinder region)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ twice a year for 2 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 2 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months to 12 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lytA+<br/> ermB–/mefA/E–<br/> ermB+/mefA/E–<br/> ermB–/mefA/E+<br/> ermB+/mefA/E+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Macrolide resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and 24 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tanzania (Kongwa district)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>E coli</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rectal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Erythromycin </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 1, 3, and 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Gambia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 3 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ once a year for 1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less than 15 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae<br/> S aureus</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Clindamycin </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention group: 1 month before and 1 month and 6 months after 3rd annual round of MDA<br/> Comparator group: 30 months after 1 annual round of MDA </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia (Goncho Siso Enese woreda district, Amhara zone)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ every 3 months for 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ (control communities treated at 12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i><br/> mefA+/ermB2<br/> mefA+/ermB+ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Clindamycin<br/> Penicillin<br/> Tetracycline </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline and 12 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethiopia (Goro district of the Gurage zone of southern Ethiopia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ twice a year for 3 years </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No AZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>S pneumoniae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharynx</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngeal swab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZ<br/> Tetracycline<br/> Penicillin<br/> TMP‐SMX </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24, 36, 42, and 54 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AZ: azithromycin<br/> MDA: mass drug administration<br/> TMP‐SMX: trimethoprim‐sulfamethoxazole  </p> <p>*All the studies were cluster‐randomised trials, and AZ was delivered to the whole community (mass drug administration). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Studies reporting antibiotic resistance: characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Antibiotic resistance to Streptococcus pneumoniae </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention***</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence intervals</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b>‐‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/400</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4 to 33.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 to 9.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 to 9.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7 to 244</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 to 2922</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CLINDAMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 to 11.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 to 12.1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>PENICILLIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 to 8.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 to 9.52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 to 72.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>TETRACYCLINE</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 to 2.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. "><b>TANA</b> </a><b> (as a percentage pneumococcal isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 to 2.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 to 6.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>TRIMETHOPRIM‐SULFAMETHOXAZOLE</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 to 2.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 2.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. "><b>TEF</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin<br/> MDA: mass drug administration </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared AZ once a year for 3 years with AZ once a year for 1 year; <a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> compared AZ every 3 months for 12 months with no AZ; <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> compared AZ twice a year for 3 years with no AZ.<br/> **Follow‐up is months after baseline (i.e. first MDA) unless otherwise indicated.<br/> ***<a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> and <a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> reported average percentages across communities, and these are the percentages reported in this table. We estimated n/N using these percentages and additional information in the text of the paper. Figures for n/N were used to calculate the risk ratio and 95% confidence interval in RevMan 5. There may be minor discrepancies due to rounding between the raw numbers, percentages and risk ratios. The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with pneumococcal carriage only.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Antibiotic resistance to Streptococcus pneumoniae </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Antibiotic resistance to Staphylococcus aureus </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence interval***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/414</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after annual round of MDA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. "><b>PRET The Gambia</b> </a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 to 11.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142/161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 to 7.1</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CLINDAMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/414</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after 3rd annual round of MDA<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128/417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/343</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/375</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 to 24.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month before 3rd annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month after annual round of MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128/161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a><b>(as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months after 3rd annual round of MDA (intervention group)<br/> 30 months after 1 annual round of MDA (comparator group) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 to 16.5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin<br/> MDA: mass drug administration </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> compared AZ once a year for three years with AZ once a year for one year.<br/> **Follow‐up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.<br/> ***The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with <i>S.aureus</i> carriage only.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Antibiotic resistance to Staphylococcus aureus </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0015"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antibiotic resistance to Escherichia coli </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up**</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>95% confidence intervals***</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of communities</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n/N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>AZITHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 1.04</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79/129</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 4.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 to 4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/324</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1 to 4.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 to 3.4</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>ERYTHROMYCIN</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 to 2.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98/129</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 to 13.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/126</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3 to 6.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/300</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 to 1.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8 to 9.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149/347</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/324</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 to 5.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. "><b>PRET Tanzania</b> </a><b> (as a percentage of isolates)¶</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 to 4.1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>n/N: number of isolates with resistance/total number of isolates<br/> AZ: azithromycin </p> <p>*Studies were all cluster‐randomised controlled trials. <a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> compared AZ once a year for three years with no AZ.<br/> **Follow‐up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.<br/> ***The 95% confidence intervals for the risk ratio are not adjusted for the cluster design. </p> <p>¶ Denominator is isolates with <i>E.coli</i> carriage only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antibiotic resistance to Escherichia coli </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0016"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse effects: cluster‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic (number of communities and people treated)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Report</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1, 2 &amp; 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0001" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Egypt</a>; <a href="./references#CD001860-bbs2-0002" title="SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 Tanzania</a>; <a href="./references#CD001860-bbs2-0003" title="Fraser‐HurtN , BaileyRL , CousensS , MabeyD , FaalH , MabeyDC . Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bulletin of the World Health Organization2001;79(7):632‐40. SchachterJ , WestSK , MabeyDC , DawsonCR , BoboL , BaileyR , et al. Azithromycin in control of trachoma. Lancet1999;354(9179):630‐5. ">ACT 1999 The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (6 communities, approximately 3800)</p> <p>Tetracycline (6 communities, approximately 2400)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0004" title="AtikB , ThanhTT , LuongVQ , LagreeS , DeanD . Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA2006;296(12):1488‐97. ">Atik 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 4 communities included in the study. </p> <p>Azithromycin (214)</p> <p>Tetracycline (161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0015" title="NCT00618449 . Impact of two alternative dosing strategies for trachoma control in Niger. clinicaltrials.gov/ct2/show/NCT00618449 (first received 20 February 2008). ">NCT00618449</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (1139)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported no adverse events on clinical trials register (clinicaltrials.gov/ct2/show/results/NCT00618449)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, approximately 6000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report, but "a data and safety monitoring committee met annually to review results and serious adverse events" </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0018" title="SeidmanJC , ColesCL , SilbergeldEK , LevensJ , MkochaH , JohnsonLB , et al. Increased carriage of macrolide‐resistant fecal E. coli following mass distribution of azithromycin for trachoma control. International Journal of Epidemiology2014;43(4):1105‐13. SeidmanJC , JohnsonLB , LevensJ , MkochaH , MunozB , SilbergeldEK , et al. Longitudinal comparison of antibiotic resistance in diarrheagenic and non‐pathogenic Escherichia coli from young Tanzanian children. Frontiers in Microbiology2016;7:1420. YohannanJ , MunozB , MkochaH , GaydosCA , BaileyR , LietmanTA , et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmology2013;131(4):431‐6. ">PRET Tanzania</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (32 communities, approximately 12,000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no serious adverse events reported in either arm."</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0019" title="BojangE , JafaliJ , PerretenV , HartJ , Harding‐EschEM , SillahA , et al. Short‐term increase in prevalence of nasopharyngeal carriage of macrolide‐resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiology2017;17:75. BurrSE , HartJ , EdwardsT , Harding‐EschEM , HollandMJ , MabeyDC , et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health2014;14:1176. BurrSE , HartJD , EdwardsT , BaldehI , BojangE , Harding‐EschEM , et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Neglected Tropical Diseases2013;7(7):e2347. BurrSE , MilneS , JafaliJ , BojangE , RajasekharM , HartJ , et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross‐sectional surveys in the Gambia. Bulletin of the World Health Organization2014;92(7):490‐8. Harding‐EschE , Jofre‐BonetM , DhanjalJK , BurrS , EdwardsT , HollandM , et al. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. PLoS Neglected Tropical Diseases2015;9(4):e0003670. Harding‐EschEM , EdwardsT , MkochaH , MunozB , HollandMJ , BurrSE , et al. Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases2010;4(11):e861. Harding‐EschEM , SillahA , EdwardsT , BurrSE , HartJD , JoofH , et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases2013;7(6):e2115. HartJD , EdwardsT , BurrSE , Harding‐EschEM , TakaokaK , HollandMJ , et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Tropical Medicine and International Health2014;19(2):207‐11. ">PRET The Gambia</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, 29,091)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0020" title="ResnikoffS , PeyramaureF , BagayogoCO , HuguetP . Health education and antibiotic therapy in trachoma control. Revue Internationale du trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique1995;7289‐98:101‐10. ">Resnikoff 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline (346)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No comment on adverse effects in report</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (over 16,000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"We recorded no reported serious adverse events attributed to study medication. 96 deaths were recorded in subkebeles in the children‐treated group and 126 deaths recorded in those in the control group. At 12 months a survey was undertaken to assess adverse effects in the treated population (n=671, 96 side‐effects reported). [.. ] 56 (11.3%) patients reported abdominal pain, vomiting, and nausea, whereas diarrhoea, constipation and related issues accounted for 16 (2.4%) of complaints. Four (0.6%) patients reported haemorrhoid or other as side effects" (House and colleagues, page 1115). "In a trachoma‐endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children" (Porco and colleagues, conclusion of abstract) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (16 communities, 4790)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"There were no serious adverse events due to the study medicine reported"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0025" title="WilsonN , GoodhewB , MkochaH , JosephK , BandeaC , BlackC , et al. Evaluation of a single dose of azithromycin for trachoma in low‐prevalence communities. Ophthalmic Epidemiology2019;26(1):1‐6. ">Wilson 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (48 communities, unclear how many people)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No serious adverse events were associated with MDA."</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>MDA: mass drug administration</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse effects: cluster‐randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0017"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Azithromycin (single‐dose) every 3 months for 12 months: mean community prevalence of infection with C trachomatis at 12 months</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Intervention: children aged 1 to 10 years offered single‐dose oral  azithromycin every 3 months (n = 12 communities) </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator: everyone aged 1 year and older offered single‐dose oral azithromycin at first visit (baseline) (n = 12 communities) </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence % </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence %</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 6.4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 to 22.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults aged 11 years and older</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 to 11.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Azithromycin (single‐dose) every 3 months for 12 months: mean community prevalence of infection with C trachomatis at 12 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0018"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Azithromycin (single‐dose) every 6 months compared with annual treatment: mean community prevalence of infection with C trachomatis </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Intervention: everyone aged 1 year and older offered single‐dose oral azithromycin every 6 months</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Comparator: everyone aged 1 year and older offered single‐dose oral azithromycin annually</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence % </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prevalence %</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a><br/> Children aged 0 to 5 years<br/> Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 to 6.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 to 9.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0017" title="AmzaA , KadriB , NassirouB , CotterSY , StollerNE , WestSK , et al. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. British Journal of Ophthalmology2018;102(5):680‐6. AmzaA , KadriB , NassirouB , CotterSY , StollerNE , ZhouZ , et al. A cluster‐randomized trial to assess the efficacy of targeting trachoma treatment to children. Clinical Infectious Diseases2017;64(6):743‐50. AmzaA , KadriB , NassirouB , StollerNE , YuSN , ZhouZ , et al. Community risk factors for ocular Chlamydia infection in Niger: pre‐treatment results from a cluster‐randomized trachoma trial. PLoS Neglected Tropical Diseases2012;6(4):e1586. AmzaA , KadriB , NassirouB , YuSN , StollerNE , BhosaiSJ , et al. The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger. PLoS Neglected Tropical Diseases2013;7(1):e1983. AmzaA , YuSN , KadriB , NassirouB , StollerNE , ZhouZ , et al. Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster‐randomized trial. PLoS Neglected Tropical Diseases2014;8(9):e3128. GaynorBD , AmzaA , GebresailassieS , KadriB , NassirouB , StollerNE , et al. Importance of including borderline cases in trachoma grader certification. American Journal of Tropical Medicine and Hygiene2014;91(3):577‐9. KeenanJD , ChinSA , AmzaA , KadriB , NassirouB , CevallosV , et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster‐randomized trial. Clinical Infectious Diseases2018;67(11):1743‐9. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection. Parasites and Vectors2015;8(1):535. LiuF , PorcoTC , AmzaA , KadriB , NassirouB , WestSK , et al. Short‐term forecasting of the prevalence of trachoma: expert opinion, statistical regression, versus transmission models. PLoS Neglected Tropical Diseases2015;9(8):e0004000. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of The PRET cluster‐randomized trial in Niger. Pediatric Infectious Disease Journal2018;37(11):1082‐6. O'BrienKS , CotterSY , AmzaA , KadriB , NassirouB , StollerNE , et al. Mass azithromycin and malaria parasitemia in Niger: results from a community‐randomized trial. American Journal of Tropical Medicine and Hygiene2017;97(3):696‐701. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Annual versus biannual mass azithromycin distribution and malaria parasitemia during the peak transmission season among children in Niger. Pediatric Infectious Disease Journal2018;37(6):506‐10. OldenburgCE , AmzaA , KadriB , NassirouB , CotterSY , StollerNE , et al. Comparison of mass azithromycin coverage targets of children in Niger: a cluster‐randomized trachoma trial. American Journal of Tropical Medicine and Hygiene2018;98(2):389‐95. StollerNE , AmzaA , BoubacarK , BeidoN , YuSN , KeenanJD , et al. Childhood mortality in communities treated with azithromycin for trachoma control in Niger. American Journal of Tropical Medicine and Hygiene2014;91(5 Suppl 1):323. YuSN , AmzaA , KadriB , NassirouB , ZhouZ , StollerNE , et al. Does higher mass antibiotic treatment coverage for trachoma reduce chlamydial infection among children? results from Pret‐Niger. American Journal of Tropical Medicine and Hygiene2014;91:317‐8. ">PRET Niger</a><br/> Adults aged 15 years or older Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children aged 0 to 9 years  </p> <p>Follow‐up: 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a> <br/> Children aged 0 to 9 years<br/> Follow‐up: 24 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 to 2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children aged 0 to 9 years<br/> Follow‐up: 36 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.6 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children and adults aged 10 years and older  </p> <p>Follow‐up: 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 to 9.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a><br/> Children and adults aged 10 years and older <br/> Follow‐up: 24 months  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 to 2.8<br/>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 to 3.8<br/>   </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0023" title="GebreT , AyeleB , ZerihunM , GenetA , StollerNE , ZhouZ , et al. Comparison of annual versus twice‐yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster‐randomised trial. Lancet2012;379(9811):143‐51. GebreT , AyeleB , ZerihunM , HouseJI , StollerNE , ZhouZ , et al. Latrine promotion for trachoma: assessment of mortality from a cluster‐randomized trial in Ethiopia. American Journal of Tropical Medicine and Hygiene2011;85(3):518‐23. HouseJI , AyeleB , PorcoTC , ZhouZ , HongKC , GebreT , et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster‐randomised trial. Lancet2009;373(9669):1111‐8. KeenanJD , AyeleB , GebreT , MoncadaJ , StollerNE , ZhouZ , et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clinical Infectious Diseases2012;54(2):253‐6. KeenanJD , AyeleB , GebreT , ZerihunM , ZhouZ , HouseJI , et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clinical Infectious Diseases2011;52(7):883‐8. KeenanJD , SahluI , McGeeL , CevallosV , VidalJE , ChochuaS , et al. Nasopharyngeal pneumococcal serotypes before and after mass azithromycin distributions for trachoma. Journal of the Pediatric Infectious Diseases Society2016;5(2):222‐6. KeenanJD , SeeCW , MoncadaJ , AyeleB , GebreT , StollerNE , et al. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Investigative Ophthalmology and Visual Science2012;53(1):235‐40. KeenanJD , TadesseZ , GebresillasieS , ShiferawA , ZerihunM , EmersonPM , et al. Mass azithromycin distribution for hyperendemic trachoma following a cluster‐randomized trial: a continuation study of randomly reassigned subclusters (TANA II). PLoS Medicine2018;15(8):e1002633. PorcoTC , GebreT , AyeleB , HouseJ , KeenanJ , ZhouZ , et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA2009;302(9):962‐8. RayKJ , ZhouZ , CevallosV , ChinS , EnanoriaW , LuiF , et al. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiology2014;21(2):86‐91. SkaletAH , CevallosV , AyeleB , GebreT , ZhouZ , JorgensenJH , et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster‐randomized clinical trial. PLoS Medicine2010;7(12):e1000377. ">TANA</a>  </p> <p>Children and adults aged 10 years and older <br/> Follow‐up: 36 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 0.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 3.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a><br/> Children aged 1 to 5 years<br/> Follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 to 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 to 21.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0024" title="CevallosV , WhitcherJP , MeleseM , AlemayehuW , YiE , ChidambaramJD , et al. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Investigative Ophthalmology and Visual Science2012;53(9):5208‐12. ChidambaramJD , AlemayehuW , MeleseM , LakewT , YiE , HouseJ , et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA2006;295(10):1142‐6. LakewT , HouseJ , HongKC , YiE , AlemayehuW , MeleseM , et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Neglected Tropical Diseases2009;3(2):e376. LeeS , AlemayehuW , MeleseM , LakewT , LeeD , YiE , et al. Chlamydia on children and flies after mass antibiotic treatment for trachoma. American Journal of Tropical Medicine and Hygiene2007;76(1):129‐31. MeleseM , AlemayehuW , LakewT , YiE , HouseJ , ChidambaramJD , et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA2008;299(7):778‐84. MorbergDP , AlemayehuW , MeleseM , LakewT , SisayA , ZhouZ , et al. A longitudinal analysis of chlamydial infection and trachomatous inflammation following mass azithromycin distribution. Ophthalmic Epidemiology2019;26(1):19‐26. SeeCW , AlemayehuW , MeleseM , ZhouZ , PorcoTC , ShiboskiS , et al. How reliable are tests for trachoma? ‐ a latent class approach. Investigative Ophthalmology and Visual Science2011;52(9):6133‐7. ">TEF</a> <br/> Children aged 1 to 5 years<br/> Follow‐up: 24 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 to 2.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 to 12.4</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>PRET Niger: 24 communities in each group; only children aged 0 to 12 years treated in intervention group.<br/> TANA: 12 communities in each group.<br/> TEF: 8 communities in each group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Azithromycin (single‐dose) every 6 months compared with annual treatment: mean community prevalence of infection with C trachomatis </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001860-tbl-0019"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Antimicrobial resistance in non‐randomised studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Citation and location</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>C trachomatis</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0124" title="SolomonAW , MohammedZ , MassaePA , ShaoJF , FosterA , MabeyDC , et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy2005;49(11):4804‐6. ">Solomon 2005</a> </p> <p>Rombo district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in people with <i>C trachomatis</i> infection. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>956/978 residents examined at baseline; 56 with eye infection; 43 isolates from these people at baseline. </p> <p>“We conclude that no</p> <p>clinically or programmatically significant changes in C. trachomatis</p> <p>azithromycin or tetracycline susceptibilities were induced"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0115" title="HongKC , SchachterJ , MoncadaJ , ZhouZ , HouseJ , LietmanTM . Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerging Infectious Diseases2009;15(7):1088‐90. ">Hong 2009</a> </p> <p>Gurage zone, Ethiopia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Samples taken before and after treatment.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months after 4 bi‐annual mass treatment (2 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Found no significant differences in susceptibilities to azithromycin and doxycycline in 6 post‐treatment and 4 pre‐treatment samples </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0131" title="WestSK , MoncadaJ , MunozB , MkochaH , StoreyP , HardickJ , et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?. Journal of Infectious Diseases2014;210(1):65‐71. ">West 2014</a> </p> <p>Kongwa district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isolates obtained before and after mass drug administration.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 9 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Doxycycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months after 3 years of mass treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared resistance to <i>C trachomatis</i> in children with/without continuing infection and found similar levels of resistance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>S pneumoniae</i> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0117" title="LeachAJ , Shelby‐JamesTM , MayoM , GrattenM , LamingAC , CurrieBJ , et al. A prospective study of the impact of community‐based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clinical Infectious Diseases1997;24(3):356‐62. ">Leach 1997</a> </p> <p>Northern territory (Aboriginal community), Australia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children with trachoma. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 14 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Erythromycin</p> <p>(results not reported)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 3 weeks, 2 months, and 6 months following azithromycin treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 children with trachoma:</p> <p> <ul id="CD001860-list-0028"> <li> <p>1/79 resistant before treatment;</p> </li> <li> <p>6/38 at 2 to 3 weeks;</p> </li> <li> <p>10/37 at 6 months.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0107" title="FryAM , JhaHC , LietmanTM , ChaudharyJS , BhattaRC , ElliottJ , et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clinical Infectious Diseases2002;35(4):395‐402. ">Fry 2002</a> </p> <p>Western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Penicillin</p> <p>Chloramphenicol</p> <p>Sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 180 days, 5% of 104 children with 2 previous treatments carriage of azithromycin‐resistant <i>S pneumoniae</i> compared with 0% of children with 1 (150 children) or 0 (149 children) previous treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0093" title="BattSL , CharalambousBM , SolomonAW , KnirschC , MassaePA , SafariS , et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic‐resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy2003;47(9):2765‐9. ">Batt 2003</a> </p> <p>Rombe district, northern Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antimicrobial resistance assessed before and after azithromycin treatment in children.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Penicillin</p> <p>Erythromycin</p> <p>Cotrimoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months and 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"At the 2‐month and 6‐month points, macrolide‐resistant isolates were 0% and 1%, respectively"</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0109" title="GaynorBD , HolbrookKA , WhitcherJP , HolmSO , JhaHC , ChaudharyJS , et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. British Journal of Ophthalmology2003;87(2):147‐8. ">Gaynor 2003</a> </p> <p>Western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 1 year after mass distribution of azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Trimethoprim/sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No macrolide resistance observed in 50 nasopharyngeal samples positive for <i>S pneumoniae</i>. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0110" title="GaynorBD , ChidambaramJD , CevallosV , MiaoY , MillerK , JhaHC , et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. British Journal of Ophthalmology2005;89(9):1097‐9. ">Gaynor 2005</a> </p> <p>Kailali district, western Nepal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 6 months after the 3rd annual treatment with azithromycin or tetracycline or no treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> <p>Trimethoprim/sulfamethoxazole</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/163 (3%) isolates were resistant to azithromycin in the azithromycin‐treated communities compared with 0 in 126 children in tetracycline‐treated communities and 91 in untreated. Tetracycline resistance was higher in tetracycline‐treated communities (39/126, 31%) compared with 17% and 16% in azithromycin‐treated and untreated communities, respectively. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001860-bbs2-0094" title="BlochEM , WestSK , MabulaK , WeaverJ , MrangoZ , MunozB , et al. Antibiotic resistance in young children in kilosa district, Tanzania 4 years after mass distribution of azithromycin for trachoma control. American Journal of Tropical Medicine and Hygiene2017;97(3):815‐8. ">Bloch 2017</a> </p> <p>KIlosa district, Tanzania</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐sectional survey 4 years after mass distribution of azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month to 59 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance to azithromycin was observed in 14.3%, 29.0%, and 16.6% of the <i>S pneumoniae</i> , <i>S aureus</i> , and <i>E coli</i> isolates, respectively. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Antimicrobial resistance in non‐randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/full#CD001860-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001860-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any antibiotic versus control (individuals)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active trachoma at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Active trachoma at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Active trachoma at 3 months (subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oral antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Topical antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Active trachoma at 12 months (subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Topical antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.71, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ocular <i>C trachomatis</i> infection at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ocular <i>C trachomatis</i> infection at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Ocular <i>C trachomatis</i> infection at 3 months (subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Oral antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.66, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Topical antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Ocular <i>C trachomatis</i> infection at 12 months (subgroup analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Oral antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.10, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Topical antibiotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any antibiotic versus control (individuals)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001860-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral versus topical antibiotics (individuals)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active trachoma at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Active trachoma at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ocular <i>C trachomatis</i> infection at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ocular <i>C trachomatis</i> infection at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral versus topical antibiotics (individuals)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001860-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral azithromycin versus topical tetracycline (individuals)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active trachoma at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Active trachoma at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ocular <i>C trachomatis</i> infection at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ocular <i>C trachomatis</i> infection at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral azithromycin versus topical tetracycline (individuals)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001860-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral azithromycin versus control (communities)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active trachoma at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Ocular <i>C trachomatis</i> infection at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.31, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral azithromycin versus control (communities)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001860-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral azithromycin versus topical tetracycline (communities)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active trachoma at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Active trachoma at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ocular <i>C trachomatis</i> infection at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ocular <i>C trachomatis</i> infection at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral azithromycin versus topical tetracycline (communities)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001860.pub4/references#CD001860-tbl-0024">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001860.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001860-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001860-note-0024">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001860-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001860-note-0023">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001860-note-0022">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001860-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001860\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001860\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001860\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001860\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001860\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001860.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001860.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001860.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001860.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001860.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717464281"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001860.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717464285"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001860.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db88ddc539365',t:'MTc0MDcxNzQ2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 